Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2017 | Apr. 27, 2017 | |
Document Documentand Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2017 | |
Document Fiscal Year Focus | 2,017 | |
Document Fiscal Period Focus | Q1 | |
Trading Symbol | PODD | |
Entity Registrant Name | INSULET CORP | |
Entity Central Index Key | 1,145,197 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding (in shares) | 57,916,580 |
Consolidated Balance Sheets (Un
Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 |
Current Assets | ||
Cash and cash equivalents | $ 76,038 | $ 137,174 |
Short-term investments | 177,990 | 161,396 |
Accounts receivable, net | 40,648 | 28,803 |
Inventories, net | 34,333 | 35,514 |
Prepaid expenses and other current assets | 8,159 | 7,073 |
Total current assets | 337,168 | 369,960 |
Property and equipment, net | 65,279 | 44,753 |
Other intangible assets, net | 2,208 | 2,041 |
Goodwill | 39,697 | 39,677 |
Other assets | 605 | 216 |
Total assets | 444,957 | 456,647 |
Current Liabilities | ||
Accounts payable | 6,413 | 13,160 |
Accrued expenses and other current liabilities | 31,839 | 41,228 |
Deferred revenue | 1,127 | 1,309 |
Total current liabilities | 39,379 | 55,697 |
Long-term debt, net of discount | 336,762 | 332,768 |
Other long-term liabilities | 5,231 | 5,032 |
Total liabilities | 381,372 | 393,497 |
Commitments and contingencies (Note 12) | ||
Stockholders’ Equity | ||
Preferred stock, $.001 par value: Authorized: 5,000,000 shares at March 31, 2017 and December 31, 2016. Issued and outstanding: zero shares at March 31, 2017 and December 31, 2016. | 0 | 0 |
Common stock, $.001 par value: Authorized: 100,000,000 shares at March 31, 2017 and December 31, 2016. Issued and outstanding: 57,912,745 and 57,457,967 shares at March 31, 2017 and December 31, 2016, respectively | 58 | 57 |
Additional paid-in capital | 754,585 | 744,243 |
Accumulated other comprehensive loss | (657) | (726) |
Accumulated deficit | (690,401) | (680,424) |
Total stockholders’ equity | 63,585 | 63,150 |
Total liabilities and stockholders’ equity | $ 444,957 | $ 456,647 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares | Mar. 31, 2017 | Dec. 31, 2016 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, issued (in shares) | 0 | 0 |
Preferred stock, outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, issued (in shares) | 57,912,745 | 57,457,967 |
Common stock, outstanding (in shares) | 57,912,745 | 57,457,967 |
Consolidated Statements of Oper
Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Income Statement [Abstract] | ||
Revenue | $ 101,713 | $ 81,213 |
Cost of revenue | 42,315 | 37,162 |
Gross profit | 59,398 | 44,051 |
Operating expenses: | ||
Research and development | 17,500 | 12,989 |
Sales and marketing | 28,095 | 24,022 |
General and administrative | 19,111 | 14,739 |
Total operating expenses | 64,706 | 51,750 |
Operating loss | (5,308) | (7,699) |
Interest expense | 5,007 | 3,096 |
Other income (expense), net | 434 | 170 |
Interest expense, net | 4,573 | 2,926 |
Loss from continuing operations before income taxes | (9,881) | (10,625) |
Income tax expense | 96 | 64 |
Net loss from continuing operations | (9,977) | (10,689) |
Loss from discontinued operations, net of tax ($0 and $408 for the three months ended March 31, 2017 and 2016, respectively) | 0 | (1,792) |
Net loss | $ (9,977) | $ (12,481) |
Net loss per share basic and diluted: | ||
Net loss from continuing operations per share basic and diluted (in dollars per share) | $ (0.17) | $ (0.19) |
Net loss from discontinued operations per share basic and diluted (in dollars per share) | $ 0 | $ (0.03) |
Weighted-average number of shares used in calculating net loss per share (in shares) | 57,693,930 | 57,029,575 |
Consolidated Statements of Ope5
Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Income Statement [Abstract] | ||
Discontinued operations, tax | $ 0 | $ 408 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Statement of Comprehensive Income [Abstract] | ||
Net loss | $ (9,977) | $ (12,481) |
Other comprehensive income, net of tax | ||
Foreign currency translation adjustment, net of tax | 79 | 400 |
Unrealized loss on available-for-sale securities, net of tax | (10) | 0 |
Total other comprehensive income, net of tax | 69 | 400 |
Total comprehensive loss | $ (9,908) | $ (12,081) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2017 | Mar. 31, 2016 | ||
Cash flows from operating activities | |||
Net loss | $ (9,977) | $ (12,481) | |
Adjustments to reconcile net loss to net cash used in operating activities | |||
Depreciation and amortization | 3,323 | 3,422 | |
Non-cash interest and other expense | 3,994 | 1,984 | |
Stock-based compensation expense | 7,124 | 5,271 | |
Provision for bad debts | 295 | 655 | |
Other | 0 | 139 | |
Changes in operating assets and liabilities: | |||
Accounts receivable | (12,146) | 2,306 | |
Inventories | 1,175 | (2,649) | |
Prepaid expenses and other assets | (1,421) | (462) | |
Accounts payable, accrued expenses and other current liabilities | (14,226) | (8,776) | |
Deferred revenue | (87) | (882) | |
Other long-term liabilities | 111 | 956 | |
Net cash provided by (used in) operating activities | [1] | (21,835) | (10,517) |
Cash flows from investing activities | |||
Purchases of property, equipment and software | [2] | (25,679) | (3,160) |
Purchases of short-term investments | (41,347) | 0 | |
Receipts from the maturity or sale of short-term investments | 24,740 | 0 | |
Proceeds from divestiture of business, net | 0 | 4,614 | |
Net cash (used in) provided by investing activities | (42,286) | 1,454 | |
Cash flows from financing activities | |||
Principal payments of capital lease obligations | (269) | (1,340) | |
Proceeds from exercise of stock options | 6,335 | 796 | |
Payment of withholding taxes in connection with vesting of restricted stock units | (3,139) | (1,640) | |
Net cash provided by (used in) financing activities | 2,927 | (2,184) | |
Effect of exchange rate changes on cash | 58 | 210 | |
Net decrease in cash and cash equivalents | (61,136) | (11,037) | |
Cash and cash equivalents, beginning of period | 137,174 | 122,672 | |
Cash and cash equivalents, end of period | 76,038 | $ 111,635 | |
Purchases of property, equipment and software, previously recorded in accounts payable | $ 1,700 | ||
[1] | Includes 2016 activity related to discontinued operations. See note 3 to the consolidated financial statements for discussion of discontinued operations. | ||
[2] | Cash outflows from purchases of property, equipment and software for the three months ended March 31, 2017 includes $1.7 million of purchases made in prior periods that were previously included in accounts payable. |
Nature of the Business
Nature of the Business | 3 Months Ended |
Dec. 31, 2016 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of the Business | Nature of the Business Insulet Corporation, the "Company," is primarily engaged in the development, manufacturing and sale of its proprietary Omnipod Insulin Management System (“Omnipod System”), an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager ("PDM"). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to 42 inches of tubing. In contrast, the Omnipod System features only two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Company believes that the Omnipod System’s unique proprietary design and features allow people with insulin-dependent diabetes to manage their diabetes with unprecedented freedom, comfort, convenience, and ease. Commercial sales of the Omnipod System began in the United States in 2005. The Company sells the Omnipod System in the United States through direct sales to customers or through its distribution partners. The Omnipod System is currently available in multiple countries in Europe, as well as in Canada and Israel. In addition to using the Omnipod System for insulin delivery, the Company also partners with global pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. The Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, “Neighborhood Diabetes”) in June 2011 . Through Neighborhood Diabetes, the Company provided customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and had the ability to process claims as either durable medical equipment or through pharmacy benefits. In February 2016, the Company sold Neighborhood Diabetes to Liberty Medical LLC ("Liberty Medical"). Additional information regarding the disposition and treatment of the Neighborhood Diabetes business as discontinued operations is provided in Note 3 to these consolidated financial statements. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2017 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Basis of Presentation The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles (“U.S. GAAP” or "GAAP") for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2017 , or for any other subsequent interim period. The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 . Reclassification of Prior Period Balances Certain reclassifications have been made to prior period amounts to conform to the current period financial statement presentation including reclassifying internal-use capitalized software from property and equipment to other intangible assets for the year ended December 31, 2016 upon adoption of ASU 2016-19, Technical Corrections and Improvements . Use of Estimates in Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in the application of certain of its significant accounting policies that may materially affect the reported amounts of assets, liabilities, equity, revenue and expenses. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, acquired businesses, accounts receivable, inventories, goodwill, deferred revenue, equity instruments, convertible debt, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates. Foreign Currency Translation For foreign operations, asset and liability accounts are translated at exchange rates as of the balance sheet date; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments are reported in accumulated other comprehensive loss, a separate component of stockholders' equity. Gains and losses arising from transactions and revaluation of period-end balances denominated in currencies other than the local entity's functional currency are included in other income (expense), net, and were not material in the three months ended March 31, 2017 and 2016 . Exposure to gains and losses from such transactions and revaluations are primarily related to Canadian dollar exchange rate fluctuations. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. Cash and Cash Equivalents For the purpose of the financial statement classification, the Company considers all highly-liquid investment instruments with original maturities of 90 days or less, when purchased, to be cash equivalents. Cash equivalents include money market mutual funds, corporate bonds, and certificates of deposit which are carried at cost which approximates their fair value. Included in the Company's cash and cash equivalents are amounts set aside for collateral on outstanding letters of credit, related to security deposits for lease obligations, totaling $1.2 million as of March 31, 2017 and December 31, 2016 . Short-term Investments Short-term investment securities consist of available-for-sale marketable securities and are carried at fair value with unrealized gains or losses included as a component of other comprehensive loss in stockholders' equity. Investments, exclusive of cash equivalents, with a stated maturity date of one year or less from the balance sheet date or that are expected to be used in current operations, are classified as short-term investments. Short-term investments include U.S. government and agency bonds, corporate bonds, and certificates of deposit. The Company reviews investments for other-than-temporary impairment when the fair value of an investment is less than its amortized cost. If an available-for-sale security is other than temporarily impaired, the loss is charged to earnings. Property and Equipment Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the respective assets. Leasehold improvements are amortized over their useful life or the life of the lease, whichever is shorter. Assets acquired under capital leases are amortized in accordance with the respective class of owned assets and the amortization is included with depreciation expense. Maintenance and repair costs are expensed as incurred. Property and equipment included $42.0 million and $39.0 million of accumulated depreciation as of March 31, 2017 and December 31, 2016 , respectively. Business Combinations The Company recognizes the assets and liabilities assumed in business combinations on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets, including intangible assets, using a variety of methods and each asset is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of intangible assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant’s use of the asset and the appropriate discount rates for a market participant. Assets recorded from the perspective of a market participant that are determined to not have economic use for the Company are expensed immediately. Any excess purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. Transaction costs and restructuring costs associated with a business combination are expensed as incurred. Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company has concluded that their Chief Executive Officer is the CODM as he is the ultimate decision maker for key operating decisions, determining the allocation of resources and assessing the financial performance of the Company. These decisions, allocations and assessments are performed by the CODM using consolidated financial information. Consolidated financial information is utilized by the CODM as the Company’s current product offering primarily consists of drug delivery and the Omnipod System. The Company’s products are relatively consistent and manufacturing is centralized and consistent across product offerings. Based on these factors, key operating decisions and resource allocations are made by the CODM using consolidated financial data and as such the Company has concluded that they operate as one segment. Goodwill Goodwill represents the excess of the cost of acquired businesses over the fair value of identifiable net assets acquired. The Company follows the provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification (“ASC”) 350-20, Intangibles - Goodwill and Other (“ASC 350-20”). The Company performs an assessment of its goodwill for impairment on at least an annual basis or whenever events or changes in circumstances indicate there might be impairment. The Company's annual impairment test date is October 1st. The majority of the Company's goodwill resulted from the acquisition of Neighborhood Diabetes in June 2011. This goodwill largely reflects operational synergies and expansion of product offerings across markets complementary to the existing core Omnipod offerings. As the Company operates in one segment, the Company has considered whether that segment contains multiple reporting units. The Company has concluded that there is a single reporting unit as the Company does not have segment managers and discrete financial information below consolidated results is not reviewed on a regular basis. Based on this conclusion, goodwill is tested for impairment at the enterprise level. The Company has the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of its sole reporting unit is less than its carrying amount. This qualitative analysis is used as a basis for determining whether it is necessary to perform the two-step goodwill impairment analysis. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the two-step goodwill impairment test will be performed. The first step compares the carrying value of the reporting unit to its fair value using a discounted cash flow analysis. If the reporting unit’s carrying value exceeds its fair value, the Company would record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. There was no impairment of goodwill during the three months ended March 31, 2017 and 2016 . Revenue Recognition The Company generates the majority of its revenue from sales of its Omnipod System to customers and third-party distributors who resell the products to patients with diabetes, and to a lesser extent from product sales to pharmaceutical companies who use the Company’s technology as a delivery method for their pharmaceuticals. Revenue recognition requires that persuasive evidence of a sales arrangement exists, delivery of goods occurs through transfer of title and risk and rewards of ownership, the selling price is fixed or determinable and collectability is reasonably assured. With respect to these criteria: • The evidence of an arrangement generally consists of a physician order form, a patient information form and, if applicable, third-party insurance approval for sales directly to patients or a purchase order for sales to a third-party distributor. • Transfer of title and risk and rewards of ownership are passed to the patient or third-party distributor upon shipment of the products. • The selling prices for all sales are fixed and agreed with the patient or third-party distributor and, if applicable, the patient’s third-party insurance provider(s) prior to shipment and are based on established list prices or, in the case of certain third-party insurers, contractually agreed upon prices. Provisions for discounts, rebates and other adjustments to customers are established as a reduction to revenue in the same period the related sales are recorded. The Company offers a 45 -day right of return for sales of its Omnipod System in the United States, and a 90 -day right of return for sales of its Omnipod System in Canada to new patients and defers revenue to reflect estimated sales returns in the same period that the related product sales are recorded. Returns are estimated through a comparison of the Company’s historical return data to its related sales. Historical rates of return are adjusted for known or expected changes in the marketplace when appropriate. When doubt exists about reasonable assuredness of collectability from specific customers, the Company defers revenue from sales of products to those customers until payment is received. As of March 31, 2017 and December 31, 2016 , the Company had deferred revenue of $1.8 million and $1.9 million , respectively, which included $0.7 million and $0.6 million classified in other long-term liabilities as of March 31, 2017 and December 31, 2016 , respectively. Deferred revenue primarily relates to undelivered elements within certain of the Company's developmental arrangements and other instances where the Company has not yet met the revenue recognition criteria. Collaborative Arrangements The Company enters into collaborative arrangements for ongoing initiatives to develop products. Although the Company does not consider any individual alliance to be material, certain of the more notable alliances are described below. Eli Lilly and Company and Concentrated Insulins : In May 2013 and January 2016, the Company entered into agreements with Eli Lilly and Company to develop new versions of the Omnipod tubeless insulin delivery system specifically designed to deliver a concentrated form of insulin used by higher insulin-requiring patients with diabetes. Under the terms of these arrangements, the parties share the responsibility of the permissible costs that are incurred. Consideration received and payments made by the Company under the terms of the arrangements are recorded within research and development expense. Shipping and Handling Costs The Company does not typically charge its customers for shipping and handling costs associated with shipping its product to its customers unless non-standard shipping and handling services are requested. These shipping and handling costs are included in general and administrative expenses and were $1.3 million and $1.0 million for the three months ended March 31, 2017 and 2016 , respectively. Concentration of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, short-term investments and accounts receivable. The Company maintains the majority of its cash and short-term investments with one financial institution. Accounts are partially insured up to various amounts mandated by the Federal Deposit Insurance Corporation or by the foreign country where the account is held. The Company purchases Omnipod Systems from Flex Ltd., its single source contract manufacturer. As of March 31, 2017 and December 31, 2016 , liabilities to this vendor represented approximately 9% and 16% of the combined balance of accounts payable, accrued expenses and other current liabilities, respectively. Revenue for customers comprising more than 10% of total revenue were as follows: Three Months Ended March 31, 2017 2016 Amgen, Inc. 15% 17% Ypsomed Distribution AG 21% 15% RGH Enterprises, Inc. 10% 10% Recent Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). ASU 2014-09 requires that a company recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. Under this guidance, a company makes additional estimates regarding performance conditions and the allocation of variable consideration and must evaluate whether revenue derived from a contract should be recognized at a point in time or over time. The guidance is effective in fiscal years beginning January 1, 2018, with early adoption permitted. The Company plans to adopt the standard as of the required effective date. The Company is currently evaluating the impact of ASU 2014-09. As part of the Company's assessment work to-date, the Company has formed an implementation work team, completed training on the new ASU’s revenue recognition model and is continuing its contract review and documentation, for which to date the Company has made significant progress. Over the course of 2017, the Company plans to finalize its evaluation and implement any required policy, process, and internal control changes required as a result of that evaluation. The new standard permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company has not yet selected a transition method nor has it determined the full effect of the standard on its consolidated financial position and results of operations. While the Company continues to assess all potential impacts of the new standard on its contracts, it currently understands that the treatment of contract acquisition and fulfillment costs will be affected as such costs are generally capitalized and amortized over the contract life under ASU 2014-09. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory ("ASU 2015-11"). ASU 2015-11 amends existing guidance and requires entities to measure most inventory at the lower of cost and net realizable value. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. Upon adoption, entities must disclose the nature of and reason for the accounting change. The Company adopted ASU 2015-11 on January 1, 2017 and its adoption did not have an impact on the consolidated financial statements. In January 2016, the FASB issued ASU 2016-01 ("ASU 2016-01"), Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities . ASU 2016-01 changes the current GAAP model for the accounting of equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. All equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income (loss)) for equity securities with readily determinable fair values. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The classification and measurement guidance will be effective in fiscal years beginning after December 15, 2017, and interim periods within those years. The Company is currently evaluating the impact of ASU 2016-01. In February 2016, the FASB issued ASU No. 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 requires lessees to recognize the assets and liabilities on their balance sheet for the rights and obligations created by most leases and continue to recognize expenses on their income statements over the lease term. It will also require disclosures designed to give financial statement users information on the amount, timing, and uncertainty of cash flows arising from leases. The guidance is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. The Company is currently evaluating the impact of ASU 2016-02. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"). ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is effective for annual reporting periods beginning after December 15, 2016, and interim periods within those years. Early adoption is permitted for all entities. The Company adopted ASU 2016-09 on January 1, 2017 and its adoption resulted in the Company increasing its deferred tax assets (tax effected) by approximately $23.8 million , which is offset by a full valuation allowance. Overall, adoption of the standard did not have a material impact on the Company's consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force) ("ASU 2016-15") . ASU 2016-15 clarifies how entities should classify certain cash receipts and cash payments on the statement of cash flows. The guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than one class of cash flows. The guidance is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted for all entities. The Company is currently evaluating the impact of ASU 2016-15 but does not expect it to be material to the consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230), Restricted Cash (a consensus of the Emerging Issues Task Force) ("ASU 2016-18"). ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The guidance is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted for all entities. The Company is currently evaluating the impact of ASU 2016-18 but does not expect it to be material to the consolidated financial statements. In December 2016, the FASB issued ASU 2016-19, Technical Corrections and Improvements ("ASU 2016-19") . ASU 2016-19 includes numerous technical corrections and clarifications to GAAP that are designed to remove inconsistencies in the board’s accounting guidance. Several provisions in this accounting guidance were effective immediately which did not have an impact on the Company’s consolidated financial statements. Additional provisions in this accounting guidance are effective for the Company in annual financial reporting periods beginning after December 15, 2016 including the clarification that the license of internal-use software shall be accounted for as the acquisition of an intangible asset. The standard allows for prospective or retrospective adoption and the Company has elected retrospective adoption. As a result of adoption, the Company has reclassified $1.5 million of internal-use software, which is net of accumulated depreciation of $2.6 million from property and equipment to other intangible assets as of December 31, 2016. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350), Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). ASU 2017-04 simplifies the accounting for goodwill impairment for all entities by eliminating the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value. The standard does not change the guidance on completing today's Step 1 of the goodwill impairment test. An entity will still be able to perform today’s optional qualitative goodwill impairment assessment before determining whether to proceed to Step 1. The guidance is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. Early adoption is permitted for all entities. The Company is currently evaluating the impact of ASU 2017-04 but does not expect it to be material to the consolidated financial statements. Other Significant Policies: The following table identifies the Company's other significant accounting policies and the note and page where a detailed description of each policy can be found. Fair Value Measurements Note 4 Page Convertible Debt Note 6 Page Accounts Receivable and Allowance for Doubtful Accounts Note 8 Page Inventories Note 9 Page Other Intangible Assets Note 10 Page Accrued Expenses and Other Current Liabilities - Product Warranty Costs Note 11 Page Commitments and Contingencies Note 12 Page Equity- Stock-Based Compensation Note 13 Page Income Taxes Note 14 Page |
Discontinued Operations
Discontinued Operations | 3 Months Ended |
Mar. 31, 2017 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Discontinued Operations | Discontinued Operations In February 2016, the Company sold Neighborhood Diabetes to Liberty Medical for approximately $6.2 million in cash, which included $1.2 million of closing adjustments finalized in June 2016 and paid by Liberty Medical. The results of operations, assets, and liabilities of Neighborhood Diabetes, are classified as discontinued operations for all periods presented, except for certain corporate overhead costs which remain in continuing operations. In connection with the 2016 disposition, the Company entered into a transition services agreement pursuant to which Insulet provided various services to Liberty Medical on an interim transitional basis. The services generally commenced on the closing date and terminated six months following the closing. Services provided by Insulet included certain information technology and back office support. The charges for such services were generally intended to allow the service provider to recover all out-of-pocket costs. Billings by Insulet under the transition services agreement were recorded as a reduction of the costs to provide the respective service in the applicable expense category in the consolidated statements of operations. This transitional support provided Liberty Medical the time required to establish its stand-alone processes for such activities that were previously provided by Insulet as described above and does not constitute significant continuing support of Liberty Medical's operations. Total expenses incurred for such transition services, which were reimbursed in full, were $0.3 million for the three months ended March 31, 2016 . No expenses were incurred for such transition services for the three months ended March 31, 2017 . Following the disposition, the Company entered into a distribution agreement with the Neighborhood Diabetes subsidiary of Liberty Medical to continue to act as a distributor for the Company's products. Omnipod System sales transacted through Neighborhood Diabetes prior to the divestiture that were previously eliminated in consolidation was $0.3 million for the three months ended March 31, 2016 . This amount was historically reported in the Neighborhood Diabetes revenue results and is being presented based on current market terms of products sold to the Neighborhood Diabetes subsidiary of Liberty Medical. Post divestiture, Omnipod System sales to the Neighborhood Diabetes subsidiary of Liberty Medical were $0.4 million for the three months ended March 31, 2016 . There were no sales to the Neighborhood Diabetes subsidiary of Liberty Medical for the three months ended March 31, 2017 . The following is a summary of the operating results of Neighborhood Diabetes included in discontinued operations for the three months ended March 31, 2016 : (In thousands) Three Months Ended March 31, 2016 Discontinued operations: Revenue (1) $ 7,730 Cost of revenue 5,369 Gross profit 2,361 Operating expenses: Sales and marketing 1,536 General and administrative (2) 2,081 Total operating expenses 3,617 Operating loss (1,256 ) Interest and other income (expense), net (128 ) Loss from discontinued operations before taxes (1,384 ) Income tax expense 408 Net loss from discontinued operations $ (1,792 ) (1) Revenue includes revenue from the operations of Neighborhood Diabetes through date of sale in February 2016. (2) Includes $1.3 million loss on sale of Neighborhood Diabetes. There were no results from discontinued operations for Neighborhood Diabetes for the three months ended March 31, 2017 . Depreciation and amortization expense included in discontinued operations was $0.1 million for the three months ended March 31, 2016 . There was no depreciation and amortization expense included in discontinued operations for the three months ended March 31, 2017 . Net operating cash flows used in discontinued operations in the three months ended March 31, 2016 was $2.0 million . There was no net operating cash flows used in discontinued operations in the three months ended March 31, 2017 . |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2017 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements The Company adopted the FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) related to the fair value measurement of certain of its assets and liabilities. ASC 820 defines fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A single estimate of fair value results from a complex series of judgments about future events and uncertainties and relies heavily on estimates and assumptions. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following approaches: • Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities. • Cost approach, which is based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence. • Income approach, which is based on the present value of the future stream of net cash flows. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, as described in ASC 820, of which the first two are considered observable and the last unobservable: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — observable inputs other than quoted prices in active markets for identical assets or liabilities Level 3 — unobservable inputs in which there is little or no market data available, which require the reporting entity to develop its own assumptions Certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and other liabilities are carried at cost, which approximates their fair value because of the short-term maturity of these financial instruments. The following table provides a summary of assets that are measured at fair value as of March 31, 2017 and December 31, 2016 , aggregated by the level in the fair value hierarchy within which those measurements fall: Fair Value Measurements (in thousands) Total Level 1 Level 2 Level 3 March 31, 2017 Recurring fair value measurements: Cash equivalents: Money market mutual funds $ 63,445 $ 63,445 $ — $ — Corporate bonds 3,833 — 3,833 — Certificates of deposit — — — — Total cash equivalents $ 67,278 $ 63,445 $ 3,833 $ — Short-term investments: U.S. government and agency bonds $ 99,752 $ 67,414 $ 32,338 $ — Corporate bonds 53,884 — 53,884 — Certificates of deposit 24,354 — 24,354 — Total short-term investments $ 177,990 $ 67,414 $ 110,576 $ — December 31, 2016 Recurring fair value measurements: Cash equivalents: Money market mutual funds $ 93,467 $ 93,467 $ — $ — Corporate bonds 4,203 — 4,203 — Certificates of deposit 735 — 735 — Total cash equivalents $ 98,405 $ 93,467 $ 4,938 $ — Short-term investments: U.S. government and agency bonds $ 79,093 $ 49,963 $ 29,130 $ — Corporate bonds 56,653 — 56,653 — Certificates of deposit 25,650 — 25,650 — Total short-term investments $ 161,396 $ 49,963 $ 111,433 $ — Debt The estimated fair value of debt is based on the Level 2 quoted market prices for the same or similar issues and included the impact of the conversion features. The carrying amounts, net of unamortized discounts and issuance costs, and the estimated fair values of the Company's convertible debt as of March 31, 2017 and December 31, 2016 are as follows: March 31, 2017 December 31, 2016 (in thousands) Carrying Value Estimated Fair Value Carrying Estimated Fair 2% Convertible Senior Notes $ 60,429 $ 75,865 $ 59,737 $ 71,909 1.25% Convertible Senior Notes $ 276,333 $ 347,556 $ 273,031 $ 320,969 |
Short-term Investments
Short-term Investments | 3 Months Ended |
Mar. 31, 2017 | |
Short-term Investments [Abstract] | |
Short-term Investments | Short-term Investments The Company's short-term investments are classified as available-for-sale and have maturity dates that range from zero months to 18 months as of March 31, 2017 . The investments are all classified as short-term as they are available for current operations. Amortized costs, gross unrealized holding gains and losses, and fair values at March 31, 2017 and December 31, 2016 are as follows: (in thousands) Amortized cost Gross Unrealized Gains Gross Unrealized Losses Fair Value March 31, 2017 U.S. government and agency bonds $ 99,922 $ — $ (170 ) $ 99,752 Corporate bonds 53,931 3 (50 ) 53,884 Certificates of deposit 24,354 — — 24,354 Total short-term investments $ 178,207 $ 3 $ (220 ) $ 177,990 December 31, 2016 U.S. government and agency bonds $ 79,211 $ — $ (118 ) $ 79,093 Corporate bonds 56,742 — (89 ) 56,653 Certificates of deposit 25,650 — — 25,650 Total short-term investments $ 161,603 $ — $ (207 ) $ 161,396 The Company had no realized gains or losses as of March 31, 2017 or December 31, 2016 . |
Convertible Debt
Convertible Debt | 3 Months Ended |
Mar. 31, 2017 | |
Debt Disclosure [Abstract] | |
Convertible Debt | Convertible Debt The Company had outstanding convertible debt and related deferred financing costs on its consolidated balance sheet as follows: As of (in thousands) March 31, 2017 December 31, 2016 Principal amount of the 2% Convertible Senior Notes $ 67,084 $ 67,084 Principal amount of the 1.25% Convertible Senior Notes 345,000 345,000 Unamortized debt discount (66,180 ) (69,684 ) Deferred financing costs (9,142 ) (9,632 ) Long-term debt, net of discount $ 336,762 $ 332,768 Interest expense related to the convertible notes was as follows: Three Months Ended March 31, (in thousands) 2017 2016 Contractual coupon interest $ 1,413 $ 1,006 Accretion of debt discount 3,504 1,702 Amortization of debt issuance costs 490 282 Total interest and other expense $ 5,407 $ 2,990 1.25% Convertible Senior Notes In September 2016, the Company issued and sold $345.0 million in principal amount of 1.25% Convertible Senior Notes, due September 15, 2021 (the " 1.25% Notes"). The interest rate on the notes is 1.25% per annum, payable semi-annually in arrears in cash on March 15 and September 15 of each year. Interest began accruing on September 13, 2016; the first interest payment was paid in March 2017. The 1.25% Notes are convertible into the Company’s common stock at an initial conversion rate of 17.1332 shares of common stock per $1,000 principal amount of the 1.25% Notes, which is equivalent to a conversion price of approximately $58.37 per share, subject to adjustment under certain circumstances. The 1.25% Notes will be convertible prior to the close of business on the business day immediately preceding June 15, 2021 only under certain circumstances and during certain periods, and will be convertible on or after June 15, 2021 until the close of business on the second scheduled trading day immediately preceding September 15, 2021, regardless of those circumstances. The Company recorded a debt discount of $ 66.7 million related to the 1.25% Notes which results from allocating a portion of the proceeds to the fair value of the conversion feature. The fair value of the debt discount was estimated using a trinomial lattice model based on the following inputs: Company's stock price, expected volatility, term to maturity, risk-free interest rate, and dividend yield. The debt discount was recorded as additional paid-in capital and the remaining liability reflects the value of the Company’s nonconvertible debt borrowing rate of 5.8% per annum. This debt discount is being amortized as non-cash interest expense over the five year term of the 1.25% Notes. The Company incurred debt issuance costs and other expenses related to this offering of approximately $11.3 million , of which $2.2 million has been reclassified as a reduction to the value of the amount allocated to equity. The remainder is presented as a reduction of debt in the consolidated balance sheet, is being amortized using the effective interest method, and is recorded as non-cash interest expense over the five year term of the 1.25% Notes. The 1.25% Notes contain provisions that allow for additional interest to holders of the notes upon failure to timely file documents or reports that the Company is required to file with the SEC. The additional interest is at a rate of 0.50% per annum of the principal amounts of the notes outstanding for a period of 360 days. If the Company merges or consolidates with a foreign entity, then additional taxes may be required to be paid by the Company under the terms of the 1.25% Notes. The Company determined that the higher interest payments required and tax payments required in certain circumstances are considered embedded derivatives and should be bifurcated and accounted for at fair value. The Company assesses the value of the embedded derivatives at each balance sheet date. The derivatives had de minimis value at the balance sheet date. Cash interest expense related to the 1.25% Notes was $1.1 million in the three months ended March 31, 2017 . Non-cash interest expense related to the 1.25% Notes was comprised of the amortization of the debt discount and debt issuance costs and was $ 3.3 million in the three months ended March 31, 2017 . As of March 31, 2017 , the Company included $276.3 million on its balance sheet in long-term debt related to the 1.25% Notes. 2% Convertible Senior Notes In June 2014, the Company issued and sold $201.3 million in principal amount of 2% Convertible Senior Notes due June 15, 2019 (the " 2% Notes"). The interest rate on the notes is 2% per annum, payable semi-annually in arrears in cash on June 15 and December 15 of each year. The 2% Notes are convertible into the Company’s common stock at an initial conversion rate of 21.5019 shares of common stock per $1,000 principal amount of the 2% Notes, which is equivalent to a conversion price of approximately $46.51 per share, subject to adjustment under certain circumstances. The Company recorded a debt discount of $35.6 million related to the 2% Notes. The debt discount was recorded as additional paid-in capital to reflect the value of the Company’s nonconvertible debt borrowing rate of 6.2% per annum. This debt discount is being amortized as non-cash interest expense over the five year term of the 2% Notes. The Company incurred deferred financing costs related to this offering of approximately $6.7 million , of which $1.2 million has been reclassified as an offset to the value of the amount allocated to equity. The remainder is recorded as a reduction to debt in the consolidated balance sheet and is being amortized as non-cash interest expense over the five year term of the 2% Notes. In September 2016, in connection with the issuance of $345 million in principal amount of the 1.25% Notes, the Company repurchased approximately $134.2 million in principal amount of the 2% Notes for $153.6 million . The extinguishment of the 2% Notes was accounted for separately from the issuance of the 1.25% Notes as both transactions were viewed as arm's-length in nature and were not contingent upon one another. The $153.6 million paid to extinguish the debt was allocated to debt and equity based on their respective fair values immediately prior to the transaction. The fair value of the debt was estimated using a trinomial lattice model based on the following inputs: Company's stock price, expected volatility, term to maturity, risk-free interest rate, and dividend yield. The Company allocated $121.4 million of the payment to the debt and $32.9 million to equity. The Company recorded a loss on extinguishment of debt of $2.6 million in connection with the repurchase and redemption of the 2% Notes during the year ended December 31, 2016, representing the excess of the $121.4 million allocated to the debt over its carrying value, net of unamortized debt discount, deferred financing costs and accrued interest. The 2% Notes contain provisions that allow for additional interest to the holders of the notes upon the failure to timely file documents or reports that the Company is required to file with the SEC. The additional interest is at a rate of 0.25% per annum of the principal amount of the notes outstanding for the first 180 days and 0.50% per annum of the principal amount of the notes outstanding for a period up to 360 days. If the Company is purchased by a company outside of the U.S., then additional taxes may be required to be paid by the Company under the terms of the 2% Notes. The Company determined that the higher interest and tax payments required in certain circumstances are considered embedded derivatives and should be bifurcated and accounted for at fair value. The Company assesses the value of the embedded derivatives at each balance sheet date. The derivatives had de minimis value at the balance sheet date. Cash interest expense related to the 2% Notes was $ 0.3 million and $ 1.0 million in the three months ended March 31, 2017 and 2016 , respectively. Non-cash interest expense related to the 2% Notes was comprised of the amortization of the debt discount and debt issuance costs and was $ 0.7 million and $2.0 million in the three months ended March 31, 2017 and 2016 , respectively. As of March 31, 2017 , the Company included $60.4 million on its balance sheet in long-term debt related to the 2% Notes. |
Net Loss Per Share
Net Loss Per Share | 3 Months Ended |
Mar. 31, 2017 | |
Disclosure Potential Common Shares Excluded From Computation Of Diluted Net Loss Per Share [Abstract] | |
Net Loss Per Share | Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, excluding unvested restricted common shares. Diluted net loss per share is computed using the weighted average number of common shares outstanding and, when dilutive, potential common share equivalents from options, restricted stock units and warrants (using the treasury-stock method), and potential common shares from convertible securities (using the if-converted method). Because the Company reported a net loss for the three months ended March 31, 2017 and 2016 , all potential dilutive common shares have been excluded from the computation of the diluted net loss per share for all periods presented, as the effect would have been anti-dilutive. Potential dilutive common share equivalents consist of the following: Three Months Ended March 31, 2017 2016 2.00% Convertible Senior Notes 1,442,433 4,327,257 1.25% Convertible Senior Notes 5,910,954 — Unvested restricted stock units 1,023,386 1,150,720 Outstanding options 3,571,559 3,594,297 Total dilutive common share equivalents 11,948,332 9,072,274 |
Accounts Receivable, Net
Accounts Receivable, Net | 3 Months Ended |
Mar. 31, 2017 | |
Receivables [Abstract] | |
Accounts Receivable, Net | Accounts Receivable, Net Accounts receivable consist of amounts due from third-party payors, patients, third-party distributors and government agencies. The Company records an allowance for doubtful accounts at the time potential collection risk is identified. The Company estimates its allowance based on historical experience, assessment of specific risk, discussions with individual customers or various assumptions and estimates that are believed to be reasonable under the circumstances. The Company believes the reserve is adequate to mitigate current collection risk. Customers that represented greater than 10% of gross accounts receivable as of March 31, 2017 and December 31, 2016 were as follows: As of March 31, 2017 December 31, 2016 Amgen, Inc. 10 % 16 % Ypsomed Distribution AG 28 % 19 % The components of accounts receivable are as follows: (in thousands) March 31, 2017 December 31, 2016 Trade receivables $ 43,348 $ 31,714 Allowance for doubtful accounts (2,700 ) (2,911 ) Total accounts receivable, net $ 40,648 $ 28,803 |
Inventories, Net
Inventories, Net | 3 Months Ended |
Mar. 31, 2017 | |
Disclosure Components Of Inventories [Abstract] | |
Inventories, Net | Inventories, Net Inventories are held at the lower of cost or market, determined under the first-in, first-out method, and include the costs of material, labor and overhead. Inventory has been recorded at cost, or net realizable value as appropriate, as of March 31, 2017 and December 31, 2016 . The Company reviews inventories for net realizable value based on quantities on hand and expectations of future use. Work in process is calculated based upon a buildup in the stage of completion using estimated labor inputs for each stage in production. The components of inventories are as follows: As of (in thousands) March 31, 2017 December 31, 2016 Raw materials $ 2,284 $ 1,911 Work-in-process 12,925 15,681 Finished goods, net 19,124 17,922 Total inventories $ 34,333 $ 35,514 |
Other Intangible Assets
Other Intangible Assets | 3 Months Ended |
Mar. 31, 2017 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Other Intangible Assets | Other Intangible Assets The Company’s finite-lived intangible assets are stated at cost less accumulated amortization. The Company assesses its intangible and other long-lived assets for impairment whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company recognizes an impairment loss for intangibles and other finite-lived assets if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows. Any such impairment loss is measured as the difference between the carrying amount and the fair value of the asset. The estimation of useful lives and expected cash flows requires the Company to make significant judgments regarding future periods that are subject to some factors outside its control. Changes in these estimates can result in significant revisions to the carrying value of these assets and may result in material charges to the results of operations. The Company recorded $2.1 million of other intangible assets in 2015 as a result of the July 2015 acquisition of its Canadian distribution business. The Company determined that the estimated useful life of the contractual relationship asset is 5 years and is amortizing the asset over the estimated lives, based on the expected cash flows of the assets. The Company adopted ASU 2016-19 on January 1, 2017 and as a result reclassified $1.5 million of internal-use software from property and equipment to other intangible assets as of December 31, 2016. The components of other intangible assets are as follows: As of March 31, 2017 December 31, 2016 (in thousands) Gross Carrying Amount Accumulated Amortization Net Book Value Gross Carrying Amount Accumulated Amortization Net Book Value Customer and contractual relationships, net (1) $ 2,011 $ (1,524 ) $ 487 $ 1,994 $ (1,466 ) $ 528 Internal-use software 4,471 (2,750 ) 1,721 4,064 (2,551 ) 1,513 Total intangible assets $ 6,482 $ (4,274 ) $ 2,208 $ 6,058 $ (4,017 ) $ 2,041 ____________________________________ (1) Includes foreign currency translation loss of approximately $0.1 million . Amortization expense for intangible assets was approximately $0.3 million and $0.1 million for the three months ended March 31, 2017 and 2016 , respectively. Amortization expense is recorded in general and administrative expenses in the consolidated statements of operations. Amortization expense expected for the next five years and thereafter is as follows: (in thousands) Years Ending December 31, Customer and Contractual Relationships Internal-Use Software (1) Total 2017 (remaining) $ 138 $ 506 $ 644 2018 157 466 623 2019 131 178 309 2020 61 7 68 Total $ 487 $ 1,157 $ 1,644 ____________________________________ (1) Excludes software in-process of development that is not currently being amortized. As of March 31, 2017 , the weighted average amortization period of the Company’s intangible assets is approximately 2.5 years . |
Accrued Expenses and Other Curr
Accrued Expenses and Other Current Liabilities | 3 Months Ended |
Mar. 31, 2017 | |
Payables and Accruals [Abstract] | |
Accrued Expenses and Other Current Liabilities | Accrued Expenses and Other Current Liabilities The components of accrued expenses and other current liabilities are as follows: (in thousands) March 31, 2017 December 31, 2016 Employee compensation and related costs $ 15,051 $ 21,999 Professional and consulting services 7,300 6,753 Supplier charges 1,893 2,886 Warranty 1,705 1,642 Other 5,890 7,948 Total accrued expenses and other current liabilities $ 31,839 $ 41,228 Product Warranty Costs The Company provides a four -year warranty on its PDMs sold in the United States and a five -year warranty on its PDMs sold in Canada and may replace any Omnipod Systems that do not function in accordance with product specifications. The Company estimates its warranty at the time the product is shipped based on historical experience and the estimated cost to service the claims. Warranty expense is recorded in cost of goods sold on the statement of operations. Cost to service the claims reflects the current product cost which has been decreasing over time. As these estimates are based on historical experience, and the Company continues to introduce new products and versions, the Company also considers the anticipated performance of the product over its warranty period in estimating warranty reserves. A reconciliation of the changes in the Company’s product warranty liability is as follows: Three Months Ended March 31, (in thousands) 2017 2016 Balance at the beginning of the period $ 4,388 $ 4,152 Warranty expense 1,463 1,028 Warranty claims settled (1,289 ) (1,020 ) Balance at the end of the period $ 4,562 $ 4,160 (in thousands) March 31, 2017 December 31, 2016 Composition of balance: Short-term $ 1,705 $ 1,642 Long-term 2,857 2,746 $ 4,562 $ 4,388 |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2017 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies The Company records a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. Operating Leases The Company leases facilities in Massachusetts, California, Tennessee, Canada and China. The Company’s leases are accounted for as operating leases. The leases generally provide for a base rent plus real estate taxes and certain operating expenses related to the leases. The Company leases approximately 100,000 square feet of laboratory and office space for its corporate headquarters in Billerica, Massachusetts. The leases expire in November 2022 and contain escalating payments over the life of the lease. Additionally, the Company leases approximately 29,000 square feet of warehousing space in Billerica, Massachusetts under a lease expiring in September 2019. The Company leases other facilities in Canada, China, California and Tennessee containing a total of approximately 11,000 square feet under leases expiring from May 2017 to January 2020. Certain of the Company’s operating lease agreements contain scheduled rent increases. Rent expense is recorded using the straight-line method and deferred rent is included in other liabilities in the accompanying balance sheets. The Company has considered ASC 840-20, Leases in accounting for these lease provisions. Rental expense under operating leases was $0.6 million for each of the three months ended March 31, 2017 and 2016 . The aggregate future minimum lease payments related to these leases as of March 31, 2017 are as follows: (in thousands) Years Ending December 31, Minimum Lease Payments 2017 (remaining) $ 2,065 2018 2,684 2019 2,681 2020 2,402 2021 2,383 Thereafter 2,131 Total $ 14,346 Legal Proceedings The Company is in the process of responding to a revised audit report received in December 2015 on behalf of the Centers for Medicare and Medicaid Services and the State of New York alleging overpayment of certain Medicaid claims to Neighborhood Diabetes. As of December 31, 2015, the Company had determined that it was probable that a loss had been incurred and recorded an aggregate liability of $0.4 million recorded within loss from discontinued operations, which was reduced to $0.3 million during 2016 (which remains the Company’s current estimate of such liability). The change in the liability was recorded in discontinued operations. In May 2016, the Company reached a settlement agreement for $0.5 million with the Connecticut Department of Social Services Office of Quality Assurance relating to an audit alleging overpayment of certain Medicaid claims to Neighborhood Diabetes. The settlement amount for this audit was consistent with the amount previously accrued. In April 2016, the Company reached a settlement agreement for $0.5 million with the Massachusetts Department of Revenue for sales and use tax audits related to Insulet Corporation, which resulted in a $0.2 million reduction of the previously recorded liability and a credit to general and administrative expenses during 2016. Between May 5, 2015 and June 16, 2015 , three class action lawsuits were filed by shareholders in the U.S. District Court, Massachusetts, against the Company and certain individual current and former executives of the Company. Two suits subsequently were voluntarily dismissed. Arkansas Teacher Retirement System v. Insulet, et al. , 1:15-cv-12345, which remains outstanding, alleges that the Company (and certain executives) committed violations of Sections 10(b) and 20(a) and Rule 10b-5 of the Securities Exchange Act of 1934 by making allegedly false and misleading statements about the Company’s business, operations, and prospects. The lawsuit seeks, among other things, compensatory damages in connection with the Company’s allegedly inflated stock price between May 7, 2013 and April 30, 2015, as well as attorneys’ fees and costs. Due in part to the preliminary nature of this matter, the Company currently cannot reasonably estimate a possible loss, or range of loss, in connection with this matter. The Company is, from time to time, involved in the normal course of business in various legal proceedings, including intellectual property, contract, employment and product liability suits. Although the Company is unable to quantify the exact financial impact of any of these matters, the Company believes that none of these currently pending matters will have an outcome material to its financial condition or business. |
Equity
Equity | 3 Months Ended |
Mar. 31, 2017 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Equity | Equity The Company accounts for stock-based compensation under the provisions of ASC 718-10, Compensation — Stock Compensation (“ASC 718-10”), which requires all share-based payments to employees and directors, including grants of stock options and restricted stock units, to be recognized in the income statement based on their fair values. Share-based payments that contain performance conditions are recognized when such conditions are probable of being achieved. The Company grants share-based awards to employees in the form of options to purchase the Company’s common stock, the ability to purchase stock at a discounted price under the employee stock purchase plan and restricted stock units. The Company uses the Black-Scholes option pricing model to determine the weighted-average fair value of options granted and determines the intrinsic value of restricted stock units based on the closing price of its common stock on the date of grant. The Company recognizes the compensation expense of share-based awards on a straight-line basis for awards with only service conditions and on an accelerated basis for awards with performance conditions. Compensation expense is recognized over the vesting period of the awards. The following table reflects the Company's stock-based compensation expense related to share-based awards recognized in the three months ended March 31, 2017 and 2016 : Three Months Ended March 31, Unamortized Expense Weighted Average Remaining Contractual Life (Years) ($ in thousands) 2017 2016 At March 31, 2017 Stock options $ 2,779 $ 2,321 $ 23,067 2.7 Restricted stock units 4,237 2,950 33,359 2.3 Employee stock purchase plan 108 — 72 0.2 Total $ 7,124 $ 5,271 $ 56,498 Stock Options In May 2007, in conjunction with the Company's initial public offering, the Company adopted its 2007 Stock Option and Incentive Plan (the "2007 Plan"). The 2007 Plan was amended and restated in November 2008, May 2012 and May 2015 to provide for the issuance of additional shares and to amend certain other provisions. Under the 2007 Plan, awards may be granted to persons who are, at the time of grant, employees, officers, non-employee directors or key persons (including consultants and prospective employees) of the Company. The 2007 Plan provides for the granting of stock options, restricted stock units, stock appreciation rights, deferred stock awards, restricted stock, unrestricted stock, cash-based awards, performance share awards or dividend equivalent rights. Options granted under the 2007 Plan generally vest over a period of four years and expire ten years from the date of grant. As of March 31, 2017 , 3,441,215 shares remain available for future issuance under the 2007 Plan. The Company awarded 34,500 shares of performance-based incentive stock options in the three months ended March 31, 2017 . There were no shares of performance-based incentive stock options awarded in the three months ended March 31, 2016 . The stock options were granted under the 2007 Plan and vest over a four year period from the grant date with the potential of an accelerated vesting period pursuant to the achievement of certain performance conditions. The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and the following assumptions, including expected volatility, expected life of the awards, the risk-free interest rate, and the dividend yield. • Expected volatility measures the amount that a stock price has fluctuated or is expected to fluctuate during a period and is computed over expected terms based upon the historical volatility of the Company's stock. • The expected life of the awards is estimated based on the midpoint scenario, which combines historical exercise data with hypothetical exercise data for outstanding options, as the Company believes this data currently represents the best estimate of the expected life of a new employee option. The Company stratifies its employee population into two groups based upon organizational hierarchy. • The risk-free interest rate assumption is based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options. • The dividend yield assumption is based on Company history and expectation of paying no dividends. The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and, therefore, used an expected dividend yield of zero in the valuation. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest. If the Company’s actual forfeiture rate is materially different from its estimate, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period. The Company evaluates the assumptions used to value the awards on a quarterly basis and if factors change and different assumptions are utilized, stock-based compensation expense may differ significantly from what has been recorded in the past. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate, increase or cancel any remaining unearned stock-based compensation expense. The estimated grant date fair values of the employee stock options were calculated using the Black-Scholes option pricing model. The following summarizes the activity under the Company’s stock option plans during the three months ended March 31, 2017 : Number of Options (#) Weighted Average Exercise Price ($) Aggregate Intrinsic Value ($ in 000s) Weighted Average Remaining Contractual Life (Years) Balance, December 31, 2016 3,441,303 $ 32.27 Granted 416,244 45.19 Exercised (1) (260,290 ) 24.34 $ 4,882 Canceled (25,698 ) 33.85 Balance, March 31, 2017 3,571,559 $ 34.35 $ 32,610 8.2 Vested, March 31, 2017 (2) 1,540,298 $ 33.17 $ 15,447 7.5 Vested and expected to vest, March 31, 2017 (2)(3) 3,275,247 $ 30,325 (1) The aggregate intrinsic value was calculated based on the positive difference between the estimated fair value of the Company’s common stock as of the date of exercise and the exercise price of the underlying options. The aggregate intrinsic value of options exercised in the three months ended March 31, 2017 and 2016 was $4.9 million and $0.8 million , respectively. (2) The aggregate intrinsic value was calculated based on the positive difference between the estimated fair value of the Company’s common stock as of March 31, 2017 , and the exercise price of the underlying options. (3) Represents the number of vested options as of March 31, 2017 , plus the number of unvested options expected to vest as of March 31, 2017 , based on the unvested options outstanding at March 31, 2017 adjusted for the estimated forfeiture. Restricted Stock Units In the three months ended March 31, 2017 , the Company awarded 330,619 restricted stock units to certain employees and non-employee members of the Board of Directors, which included 105,476 restricted stock units subject to the achievement of performance conditions (performance-based restricted stock units). For performance-based restricted stock units for which the performance criteria has not yet been achieved, the Company recognized stock compensation expense of $1.0 million in the three months ended March 31, 2017 as it expects a portion of the performance-based restricted stock units granted in 2016 and 2017 will be earned based on its evaluation of the performance criteria at December 31, 2017 and December 31, 2019, respectively. An additional $0.2 million of stock compensation expense was recognized in the three months ended March 31, 2017 for performance-based restricted stock units for which the performance criteria has been achieved. The restricted stock units were granted under the 2007 Plan and generally vest annually over a one or three year period from the grant date, except for the performance-based restricted stock units, which follow different vesting patterns. The restricted stock units granted during the three months ended March 31, 2017 have a weighted average fair value of $46.22 per share based on the closing price of the Company’s common stock on the date of grant and were valued at approximately $15.3 million on their grant date. The Company is recognizing the compensation expense over the vesting period. Approximately $3.0 million and $2.3 million in the three months ended March 31, 2017 and 2016 , respectively, of stock-based compensation expense related to the vesting of non-performance based restricted stock units was recognized. Under the terms of the awards, the Company will issue shares of common stock on each of the vesting dates. The following table summarizes the status of the Company’s restricted stock units during the three months ended March 31, 2017 : Number of Shares (#) Weighted Average Fair Value ($) Balance, December 31, 2016 962,219 $ 31.14 Granted 330,619 46.22 Vested (266,495 ) 32.03 Forfeited (2,957 ) 33.17 Balance, March 31, 2017 1,023,386 $ 35.77 Employee Stock Purchase Plan The Employee Stock Purchase Plan (“ESPP”) authorizes the issuance of up to a total of 380,000 shares of common stock to participating employees. The Company will make one or more offerings each year to eligible employees to purchase stock under the ESPP. Between January 1, 2008 and June 30, 2016, offering periods began on the first business day occurring on or after each January 1 and July 1 and ended on the last business day occurring on or before the following June 30 and December 31, respectively. Beginning as of July 1, 2016, offering periods begin on the first business day occurring on or after each December 1 and June 1 and will end on the last business day occurring on or before the following May 31 and November 30, respectively. In order to permit a transition to the new offering cycle, a one-time offering period began on July 1, 2016 and ended on November 30, 2016. Each employee who is a participant in the Company’s ESPP may purchase up to a maximum of 800 shares per offering period or $25,000 worth of common stock, valued at the start of the purchase period, per year by authorizing payroll deductions of up to 10% of his or her base salary. Unless the participating employee withdraws from the offering period, his or her accumulated payroll deductions will be used to purchase common stock. For all offering periods ending on or before June 30, 2016, the purchase price for each share purchased was 85% of the fair market value of the common stock on the last day of the offering period. For all offering periods beginning on or after July 1, 2016, the purchase price for each share purchased will be 85% of the lower of (i) the fair market value of the common stock on the first day of the offering period or (ii) the fair market value of the common stock on the last day of the offering period. The accumulated payroll deductions of any employee who is not a participant on the last day of an offering period will be refunded. An employee’s rights under the ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with the Company for any reason. The ESPP may be terminated or amended by the Board of Directors at any time. An amendment to increase the number of shares of common stock that is authorized under the ESPP, and certain other amendments, require the approval of stockholders. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2017 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect in the years in which the differences are expected to reverse. The Company reviews its deferred tax assets for recoverability considering historical profitability, projected future taxable income, and the expected timing of the reversals of existing temporary differences and tax planning strategies. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company follows the provisions of ASC 740-10, Income Taxes (“ASC 740-10”) on accounting for uncertainty in income taxes recognized in its financial statements. ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In addition, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company recognizes estimated interest and penalties for uncertain tax positions in income tax expense. The Company files federal, state and foreign tax returns. These returns are generally open to examination by the relevant tax authorities from three to four years from the date they are filed. The tax filings relating to the Company's federal and state tax returns are currently open to examination for tax years 2013 through 2015 and 2012 through 2015, respectively. In addition, the Company has generated tax losses since its inception in 2000. These years may be subject to examination if the losses are carried forward and utilized in future years. At March 31, 2017 and December 31, 2016 , the Company provided a full valuation allowance against its domestic net deferred tax asset because it is not more likely than not that the future tax benefit will be realized. In addition, the Company has a net deferred tax asset in foreign jurisdictions where no valuation allowance is recorded, because it is more likely than not that the future tax benefit will be realized. Income tax expense was $0.1 million for each of the three months ended March 31, 2017 and 2016 . Income tax expense for both periods was primarily driven by income denominated in foreign jurisdictions, mainly Canada. The Company had no unrecognized tax benefits at March 31, 2017 . |
Segment Reporting
Segment Reporting | 3 Months Ended |
Mar. 31, 2017 | |
Segment Reporting [Abstract] | |
Segment Reporting | Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company has concluded that their Chief Executive Officer is the CODM as he is the ultimate decision maker for key operating decisions, determining the allocation of resources and assessing the financial performance of the Company. These decisions, allocations and assessments are performed by the CODM using consolidated financial information. Consolidated financial information is utilized by the CODM as the Company’s current product offerings primarily consists of the Omnipod System and drug delivery. The Company’s products are relatively consistent and manufacturing is centralized and consistent across product offerings. Based on these factors, key operating decisions and resource allocations are made by the CODM using consolidated financial data and as such the Company has concluded that they operate as one segment. Worldwide revenue for the Company's products is categorized as follows: Three Months Ended March 31, (in thousands) 2017 2016 U.S. Omnipod $ 59,655 $ 50,712 International Omnipod 25,144 15,380 Drug Delivery 16,914 15,121 Total $ 101,713 $ 81,213 Geographic information about revenue, based on the region of the customer's shipping location, is as follows: Three Months Ended March 31, (in thousands) 2017 2016 United States $ 76,569 $ 65,833 All other 25,144 15,380 Total $ 101,713 $ 81,213 Geographic information about long-lived assets, net, excluding goodwill and other intangible assets is as follows: (in thousands) March 31, 2017 December 31, 2016 United States $ 43,238 $ 19,341 China 22,203 25,431 Other 71 197 Total $ 65,512 $ 44,969 |
Summary of Significant Accoun23
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2017 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles (“U.S. GAAP” or "GAAP") for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2017 , or for any other subsequent interim period. The unaudited consolidated financial statements in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 . |
Reclassification of Prior Period Balance | Reclassification of Prior Period Balances Certain reclassifications have been made to prior period amounts to conform to the current period financial statement presentation including reclassifying internal-use capitalized software from property and equipment to other intangible assets for the year ended December 31, 2016 upon adoption of ASU 2016-19, Technical Corrections and Improvements . |
Use of Estimates in Preparation of Financial Statements | Use of Estimates in Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in the application of certain of its significant accounting policies that may materially affect the reported amounts of assets, liabilities, equity, revenue and expenses. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, acquired businesses, accounts receivable, inventories, goodwill, deferred revenue, equity instruments, convertible debt, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates. |
Foreign Currency Translation | Foreign Currency Translation For foreign operations, asset and liability accounts are translated at exchange rates as of the balance sheet date; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments are reported in accumulated other comprehensive loss, a separate component of stockholders' equity. Gains and losses arising from transactions and revaluation of period-end balances denominated in currencies other than the local entity's functional currency are included in other income (expense), net, and were not material in the three months ended March 31, 2017 and 2016 . Exposure to gains and losses from such transactions and revaluations are primarily related to Canadian dollar exchange rate fluctuations. |
Principles of Consolidation | Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. |
Cash and Cash Equivalents | Cash and Cash Equivalents For the purpose of the financial statement classification, the Company considers all highly-liquid investment instruments with original maturities of 90 days or less, when purchased, to be cash equivalents. Cash equivalents include money market mutual funds, corporate bonds, and certificates of deposit which are carried at cost which approximates their fair value. |
Short-term Investments | Short-term Investments Short-term investment securities consist of available-for-sale marketable securities and are carried at fair value with unrealized gains or losses included as a component of other comprehensive loss in stockholders' equity. Investments, exclusive of cash equivalents, with a stated maturity date of one year or less from the balance sheet date or that are expected to be used in current operations, are classified as short-term investments. Short-term investments include U.S. government and agency bonds, corporate bonds, and certificates of deposit. The Company reviews investments for other-than-temporary impairment when the fair value of an investment is less than its amortized cost. If an available-for-sale security is other than temporarily impaired, the loss is charged to earnings. |
Property and Equipment | Property and Equipment Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the respective assets. Leasehold improvements are amortized over their useful life or the life of the lease, whichever is shorter. Assets acquired under capital leases are amortized in accordance with the respective class of owned assets and the amortization is included with depreciation expense. Maintenance and repair costs are expensed as incurred. |
Business Combinations | Business Combinations The Company recognizes the assets and liabilities assumed in business combinations on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets, including intangible assets, using a variety of methods and each asset is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of intangible assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant’s use of the asset and the appropriate discount rates for a market participant. Assets recorded from the perspective of a market participant that are determined to not have economic use for the Company are expensed immediately. Any excess purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. Transaction costs and restructuring costs associated with a business combination are expensed as incurred. |
Segment Reporting | Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company has concluded that their Chief Executive Officer is the CODM as he is the ultimate decision maker for key operating decisions, determining the allocation of resources and assessing the financial performance of the Company. These decisions, allocations and assessments are performed by the CODM using consolidated financial information. Consolidated financial information is utilized by the CODM as the Company’s current product offering primarily consists of drug delivery and the Omnipod System. The Company’s products are relatively consistent and manufacturing is centralized and consistent across product offerings. Based on these factors, key operating decisions and resource allocations are made by the CODM using consolidated financial data and as such the Company has concluded that they operate as one segment. Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company has concluded that their Chief Executive Officer is the CODM as he is the ultimate decision maker for key operating decisions, determining the allocation of resources and assessing the financial performance of the Company. These decisions, allocations and assessments are performed by the CODM using consolidated financial information. Consolidated financial information is utilized by the CODM as the Company’s current product offerings primarily consists of the Omnipod System and drug delivery. The Company’s products are relatively consistent and manufacturing is centralized and consistent across product offerings. Based on these factors, key operating decisions and resource allocations are made by the CODM using consolidated financial data and as such the Company has concluded that they operate as one segment. |
Goodwill | Goodwill Goodwill represents the excess of the cost of acquired businesses over the fair value of identifiable net assets acquired. The Company follows the provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification (“ASC”) 350-20, Intangibles - Goodwill and Other (“ASC 350-20”). The Company performs an assessment of its goodwill for impairment on at least an annual basis or whenever events or changes in circumstances indicate there might be impairment. The Company's annual impairment test date is October 1st. The majority of the Company's goodwill resulted from the acquisition of Neighborhood Diabetes in June 2011. This goodwill largely reflects operational synergies and expansion of product offerings across markets complementary to the existing core Omnipod offerings. As the Company operates in one segment, the Company has considered whether that segment contains multiple reporting units. The Company has concluded that there is a single reporting unit as the Company does not have segment managers and discrete financial information below consolidated results is not reviewed on a regular basis. Based on this conclusion, goodwill is tested for impairment at the enterprise level. The Company has the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of its sole reporting unit is less than its carrying amount. This qualitative analysis is used as a basis for determining whether it is necessary to perform the two-step goodwill impairment analysis. If the Company determines that it is more likely than not that its fair value is less than its carrying amount, then the two-step goodwill impairment test will be performed. The first step compares the carrying value of the reporting unit to its fair value using a discounted cash flow analysis. If the reporting unit’s carrying value exceeds its fair value, the Company would record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. |
Revenue Recognition | Revenue Recognition The Company generates the majority of its revenue from sales of its Omnipod System to customers and third-party distributors who resell the products to patients with diabetes, and to a lesser extent from product sales to pharmaceutical companies who use the Company’s technology as a delivery method for their pharmaceuticals. Revenue recognition requires that persuasive evidence of a sales arrangement exists, delivery of goods occurs through transfer of title and risk and rewards of ownership, the selling price is fixed or determinable and collectability is reasonably assured. With respect to these criteria: • The evidence of an arrangement generally consists of a physician order form, a patient information form and, if applicable, third-party insurance approval for sales directly to patients or a purchase order for sales to a third-party distributor. • Transfer of title and risk and rewards of ownership are passed to the patient or third-party distributor upon shipment of the products. • The selling prices for all sales are fixed and agreed with the patient or third-party distributor and, if applicable, the patient’s third-party insurance provider(s) prior to shipment and are based on established list prices or, in the case of certain third-party insurers, contractually agreed upon prices. Provisions for discounts, rebates and other adjustments to customers are established as a reduction to revenue in the same period the related sales are recorded. The Company offers a 45 -day right of return for sales of its Omnipod System in the United States, and a 90 -day right of return for sales of its Omnipod System in Canada to new patients and defers revenue to reflect estimated sales returns in the same period that the related product sales are recorded. Returns are estimated through a comparison of the Company’s historical return data to its related sales. Historical rates of return are adjusted for known or expected changes in the marketplace when appropriate. When doubt exists about reasonable assuredness of collectability from specific customers, the Company defers revenue from sales of products to those customers until payment is received. As of March 31, 2017 and December 31, 2016 , the Company had deferred revenue of $1.8 million and $1.9 million , respectively, which included $0.7 million and $0.6 million classified in other long-term liabilities as of March 31, 2017 and December 31, 2016 , respectively. Deferred revenue primarily relates to undelivered elements within certain of the Company's developmental arrangements and other instances where the Company has not yet met the revenue recognition criteria. |
Collaborative Arrangements | Collaborative Arrangements The Company enters into collaborative arrangements for ongoing initiatives to develop products. Although the Company does not consider any individual alliance to be material, certain of the more notable alliances are described below. Eli Lilly and Company and Concentrated Insulins : In May 2013 and January 2016, the Company entered into agreements with Eli Lilly and Company to develop new versions of the Omnipod tubeless insulin delivery system specifically designed to deliver a concentrated form of insulin used by higher insulin-requiring patients with diabetes. Under the terms of these arrangements, the parties share the responsibility of the permissible costs that are incurred. Consideration received and payments made by the Company under the terms of the arrangements are recorded within research and development expense. |
Shipping and Handling Costs | Shipping and Handling Costs The Company does not typically charge its customers for shipping and handling costs associated with shipping its product to its customers unless non-standard shipping and handling services are requested. These shipping and handling costs are included in general and administrative expenses and were $1.3 million and $1.0 million for the three months ended March 31, 2017 and 2016 , respectively. |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, short-term investments and accounts receivable. The Company maintains the majority of its cash and short-term investments with one financial institution. Accounts are partially insured up to various amounts mandated by the Federal Deposit Insurance Corporation or by the foreign country where the account is held. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). ASU 2014-09 requires that a company recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. Under this guidance, a company makes additional estimates regarding performance conditions and the allocation of variable consideration and must evaluate whether revenue derived from a contract should be recognized at a point in time or over time. The guidance is effective in fiscal years beginning January 1, 2018, with early adoption permitted. The Company plans to adopt the standard as of the required effective date. The Company is currently evaluating the impact of ASU 2014-09. As part of the Company's assessment work to-date, the Company has formed an implementation work team, completed training on the new ASU’s revenue recognition model and is continuing its contract review and documentation, for which to date the Company has made significant progress. Over the course of 2017, the Company plans to finalize its evaluation and implement any required policy, process, and internal control changes required as a result of that evaluation. The new standard permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company has not yet selected a transition method nor has it determined the full effect of the standard on its consolidated financial position and results of operations. While the Company continues to assess all potential impacts of the new standard on its contracts, it currently understands that the treatment of contract acquisition and fulfillment costs will be affected as such costs are generally capitalized and amortized over the contract life under ASU 2014-09. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory ("ASU 2015-11"). ASU 2015-11 amends existing guidance and requires entities to measure most inventory at the lower of cost and net realizable value. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. Upon adoption, entities must disclose the nature of and reason for the accounting change. The Company adopted ASU 2015-11 on January 1, 2017 and its adoption did not have an impact on the consolidated financial statements. In January 2016, the FASB issued ASU 2016-01 ("ASU 2016-01"), Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities . ASU 2016-01 changes the current GAAP model for the accounting of equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. All equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income (loss)) for equity securities with readily determinable fair values. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The classification and measurement guidance will be effective in fiscal years beginning after December 15, 2017, and interim periods within those years. The Company is currently evaluating the impact of ASU 2016-01. In February 2016, the FASB issued ASU No. 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 requires lessees to recognize the assets and liabilities on their balance sheet for the rights and obligations created by most leases and continue to recognize expenses on their income statements over the lease term. It will also require disclosures designed to give financial statement users information on the amount, timing, and uncertainty of cash flows arising from leases. The guidance is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. The Company is currently evaluating the impact of ASU 2016-02. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"). ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is effective for annual reporting periods beginning after December 15, 2016, and interim periods within those years. Early adoption is permitted for all entities. The Company adopted ASU 2016-09 on January 1, 2017 and its adoption resulted in the Company increasing its deferred tax assets (tax effected) by approximately $23.8 million , which is offset by a full valuation allowance. Overall, adoption of the standard did not have a material impact on the Company's consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force) ("ASU 2016-15") . ASU 2016-15 clarifies how entities should classify certain cash receipts and cash payments on the statement of cash flows. The guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than one class of cash flows. The guidance is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted for all entities. The Company is currently evaluating the impact of ASU 2016-15 but does not expect it to be material to the consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230), Restricted Cash (a consensus of the Emerging Issues Task Force) ("ASU 2016-18"). ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The guidance is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted for all entities. The Company is currently evaluating the impact of ASU 2016-18 but does not expect it to be material to the consolidated financial statements. In December 2016, the FASB issued ASU 2016-19, Technical Corrections and Improvements ("ASU 2016-19") . ASU 2016-19 includes numerous technical corrections and clarifications to GAAP that are designed to remove inconsistencies in the board’s accounting guidance. Several provisions in this accounting guidance were effective immediately which did not have an impact on the Company’s consolidated financial statements. Additional provisions in this accounting guidance are effective for the Company in annual financial reporting periods beginning after December 15, 2016 including the clarification that the license of internal-use software shall be accounted for as the acquisition of an intangible asset. The standard allows for prospective or retrospective adoption and the Company has elected retrospective adoption. As a result of adoption, the Company has reclassified $1.5 million of internal-use software, which is net of accumulated depreciation of $2.6 million from property and equipment to other intangible assets as of December 31, 2016. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350), Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). ASU 2017-04 simplifies the accounting for goodwill impairment for all entities by eliminating the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value. The standard does not change the guidance on completing today's Step 1 of the goodwill impairment test. An entity will still be able to perform today’s optional qualitative goodwill impairment assessment before determining whether to proceed to Step 1. The guidance is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. Early adoption is permitted for all entities. The Company is currently evaluating the impact of ASU 2017-04 but does not expect it to be material to the consolidated financial statements. Other Significant Policies: The following table identifies the Company's other significant accounting policies and the note and page where a detailed description of each policy can be found. Fair Value Measurements Note 4 Page Convertible Debt Note 6 Page Accounts Receivable and Allowance for Doubtful Accounts Note 8 Page Inventories Note 9 Page Other Intangible Assets Note 10 Page Accrued Expenses and Other Current Liabilities - Product Warranty Costs Note 11 Page Commitments and Contingencies Note 12 Page Equity- Stock-Based Compensation Note 13 Page Income Taxes Note 14 Page |
Fair Value of Financial Instruments | The Company adopted the FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) related to the fair value measurement of certain of its assets and liabilities. ASC 820 defines fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A single estimate of fair value results from a complex series of judgments about future events and uncertainties and relies heavily on estimates and assumptions. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following approaches: • Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities. • Cost approach, which is based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence. • Income approach, which is based on the present value of the future stream of net cash flows. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, as described in ASC 820, of which the first two are considered observable and the last unobservable: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — observable inputs other than quoted prices in active markets for identical assets or liabilities Level 3 — unobservable inputs in which there is little or no market data available, which require the reporting entity to develop its own assumptions Certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and other liabilities are carried at cost, which approximates their fair value because of the short-term maturity of these financial instruments. |
Accounts Receivable and Allowance for Doubtful Accounts | Accounts receivable consist of amounts due from third-party payors, patients, third-party distributors and government agencies. The Company records an allowance for doubtful accounts at the time potential collection risk is identified. The Company estimates its allowance based on historical experience, assessment of specific risk, discussions with individual customers or various assumptions and estimates that are believed to be reasonable under the circumstances. The Company believes the reserve is adequate to mitigate current collection risk. |
Inventories | Inventories are held at the lower of cost or market, determined under the first-in, first-out method, and include the costs of material, labor and overhead. Inventory has been recorded at cost, or net realizable value as appropriate, as of March 31, 2017 and December 31, 2016 . The Company reviews inventories for net realizable value based on quantities on hand and expectations of future use. Work in process is calculated based upon a buildup in the stage of completion using estimated labor inputs for each stage in production. |
Other Intangible Assets | The Company’s finite-lived intangible assets are stated at cost less accumulated amortization. The Company assesses its intangible and other long-lived assets for impairment whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company recognizes an impairment loss for intangibles and other finite-lived assets if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows. Any such impairment loss is measured as the difference between the carrying amount and the fair value of the asset. The estimation of useful lives and expected cash flows requires the Company to make significant judgments regarding future periods that are subject to some factors outside its control. Changes in these estimates can result in significant revisions to the carrying value of these assets and may result in material charges to the results of operations. |
Product Warranty Costs | The Company provides a four -year warranty on its PDMs sold in the United States and a five -year warranty on its PDMs sold in Canada and may replace any Omnipod Systems that do not function in accordance with product specifications. The Company estimates its warranty at the time the product is shipped based on historical experience and the estimated cost to service the claims. Warranty expense is recorded in cost of goods sold on the statement of operations. Cost to service the claims reflects the current product cost which has been decreasing over time. As these estimates are based on historical experience, and the Company continues to introduce new products and versions, the Company also considers the anticipated performance of the product over its warranty period in estimating warranty reserves. |
Equity | The Company accounts for stock-based compensation under the provisions of ASC 718-10, Compensation — Stock Compensation (“ASC 718-10”), which requires all share-based payments to employees and directors, including grants of stock options and restricted stock units, to be recognized in the income statement based on their fair values. Share-based payments that contain performance conditions are recognized when such conditions are probable of being achieved. The Company grants share-based awards to employees in the form of options to purchase the Company’s common stock, the ability to purchase stock at a discounted price under the employee stock purchase plan and restricted stock units. The Company uses the Black-Scholes option pricing model to determine the weighted-average fair value of options granted and determines the intrinsic value of restricted stock units based on the closing price of its common stock on the date of grant. The Company recognizes the compensation expense of share-based awards on a straight-line basis for awards with only service conditions and on an accelerated basis for awards with performance conditions. Compensation expense is recognized over the vesting period of the awards. The following table reflects the Company's stock-based compensation expense related to share-based awards recognized in the three months ended March 31, 2017 and 2016 : Three Months Ended March 31, Unamortized Expense Weighted Average Remaining Contractual Life (Years) ($ in thousands) 2017 2016 At March 31, 2017 Stock options $ 2,779 $ 2,321 $ 23,067 2.7 Restricted stock units 4,237 2,950 33,359 2.3 Employee stock purchase plan 108 — 72 0.2 Total $ 7,124 $ 5,271 $ 56,498 Stock Options In May 2007, in conjunction with the Company's initial public offering, the Company adopted its 2007 Stock Option and Incentive Plan (the "2007 Plan"). The 2007 Plan was amended and restated in November 2008, May 2012 and May 2015 to provide for the issuance of additional shares and to amend certain other provisions. Under the 2007 Plan, awards may be granted to persons who are, at the time of grant, employees, officers, non-employee directors or key persons (including consultants and prospective employees) of the Company. The 2007 Plan provides for the granting of stock options, restricted stock units, stock appreciation rights, deferred stock awards, restricted stock, unrestricted stock, cash-based awards, performance share awards or dividend equivalent rights. Options granted under the 2007 Plan generally vest over a period of four years and expire ten years from the date of grant. As of March 31, 2017 , 3,441,215 shares remain available for future issuance under the 2007 Plan. |
Fair Value Measurement | The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and the following assumptions, including expected volatility, expected life of the awards, the risk-free interest rate, and the dividend yield. • Expected volatility measures the amount that a stock price has fluctuated or is expected to fluctuate during a period and is computed over expected terms based upon the historical volatility of the Company's stock. • The expected life of the awards is estimated based on the midpoint scenario, which combines historical exercise data with hypothetical exercise data for outstanding options, as the Company believes this data currently represents the best estimate of the expected life of a new employee option. The Company stratifies its employee population into two groups based upon organizational hierarchy. • The risk-free interest rate assumption is based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options. • The dividend yield assumption is based on Company history and expectation of paying no dividends. The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and, therefore, used an expected dividend yield of zero in the valuation. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest. If the Company’s actual forfeiture rate is materially different from its estimate, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period. The Company evaluates the assumptions used to value the awards on a quarterly basis and if factors change and different assumptions are utilized, stock-based compensation expense may differ significantly from what has been recorded in the past. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate, increase or cancel any remaining unearned stock-based compensation expense. The estimated grant date fair values of the employee stock options were calculated using the Black-Scholes option pricing model. |
Income Taxes | The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect in the years in which the differences are expected to reverse. The Company reviews its deferred tax assets for recoverability considering historical profitability, projected future taxable income, and the expected timing of the reversals of existing temporary differences and tax planning strategies. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company follows the provisions of ASC 740-10, Income Taxes (“ASC 740-10”) on accounting for uncertainty in income taxes recognized in its financial statements. ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In addition, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company recognizes estimated interest and penalties for uncertain tax positions in income tax expense. The Company files federal, state and foreign tax returns. These returns are generally open to examination by the relevant tax authorities from three to four years from the date they are filed. The tax filings relating to the Company's federal and state tax returns are currently open to examination for tax years 2013 through 2015 and 2012 through 2015, respectively. In addition, the Company has generated tax losses since its inception in 2000. These years may be subject to examination if the losses are carried forward and utilized in future years. |
Summary of Significant Accoun24
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Accounting Policies [Abstract] | |
Schedule of revenue from major customers | Revenue for customers comprising more than 10% of total revenue were as follows: Three Months Ended March 31, 2017 2016 Amgen, Inc. 15% 17% Ypsomed Distribution AG 21% 15% RGH Enterprises, Inc. 10% 10% Customers that represented greater than 10% of gross accounts receivable as of March 31, 2017 and December 31, 2016 were as follows: As of March 31, 2017 December 31, 2016 Amgen, Inc. 10 % 16 % Ypsomed Distribution AG 28 % 19 % |
Discontinued Operations (Tables
Discontinued Operations (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Schedule of discontinued operations | The following is a summary of the operating results of Neighborhood Diabetes included in discontinued operations for the three months ended March 31, 2016 : (In thousands) Three Months Ended March 31, 2016 Discontinued operations: Revenue (1) $ 7,730 Cost of revenue 5,369 Gross profit 2,361 Operating expenses: Sales and marketing 1,536 General and administrative (2) 2,081 Total operating expenses 3,617 Operating loss (1,256 ) Interest and other income (expense), net (128 ) Loss from discontinued operations before taxes (1,384 ) Income tax expense 408 Net loss from discontinued operations $ (1,792 ) (1) Revenue includes revenue from the operations of Neighborhood Diabetes through date of sale in February 2016. (2) Includes $1.3 million loss on sale of Neighborhood Diabetes. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Fair Value Disclosures [Abstract] | |
Fair Value, Assets Measured on Recurring and Nonrecurring Basis | The following table provides a summary of assets that are measured at fair value as of March 31, 2017 and December 31, 2016 , aggregated by the level in the fair value hierarchy within which those measurements fall: Fair Value Measurements (in thousands) Total Level 1 Level 2 Level 3 March 31, 2017 Recurring fair value measurements: Cash equivalents: Money market mutual funds $ 63,445 $ 63,445 $ — $ — Corporate bonds 3,833 — 3,833 — Certificates of deposit — — — — Total cash equivalents $ 67,278 $ 63,445 $ 3,833 $ — Short-term investments: U.S. government and agency bonds $ 99,752 $ 67,414 $ 32,338 $ — Corporate bonds 53,884 — 53,884 — Certificates of deposit 24,354 — 24,354 — Total short-term investments $ 177,990 $ 67,414 $ 110,576 $ — December 31, 2016 Recurring fair value measurements: Cash equivalents: Money market mutual funds $ 93,467 $ 93,467 $ — $ — Corporate bonds 4,203 — 4,203 — Certificates of deposit 735 — 735 — Total cash equivalents $ 98,405 $ 93,467 $ 4,938 $ — Short-term investments: U.S. government and agency bonds $ 79,093 $ 49,963 $ 29,130 $ — Corporate bonds 56,653 — 56,653 — Certificates of deposit 25,650 — 25,650 — Total short-term investments $ 161,396 $ 49,963 $ 111,433 $ — |
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis | The carrying amounts, net of unamortized discounts and issuance costs, and the estimated fair values of the Company's convertible debt as of March 31, 2017 and December 31, 2016 are as follows: March 31, 2017 December 31, 2016 (in thousands) Carrying Value Estimated Fair Value Carrying Estimated Fair 2% Convertible Senior Notes $ 60,429 $ 75,865 $ 59,737 $ 71,909 1.25% Convertible Senior Notes $ 276,333 $ 347,556 $ 273,031 $ 320,969 |
Short-term Investments (Tables)
Short-term Investments (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Short-term Investments [Abstract] | |
Schedule of short-term investments | Amortized costs, gross unrealized holding gains and losses, and fair values at March 31, 2017 and December 31, 2016 are as follows: (in thousands) Amortized cost Gross Unrealized Gains Gross Unrealized Losses Fair Value March 31, 2017 U.S. government and agency bonds $ 99,922 $ — $ (170 ) $ 99,752 Corporate bonds 53,931 3 (50 ) 53,884 Certificates of deposit 24,354 — — 24,354 Total short-term investments $ 178,207 $ 3 $ (220 ) $ 177,990 December 31, 2016 U.S. government and agency bonds $ 79,211 $ — $ (118 ) $ 79,093 Corporate bonds 56,742 — (89 ) 56,653 Certificates of deposit 25,650 — — 25,650 Total short-term investments $ 161,603 $ — $ (207 ) $ 161,396 |
Convertible Debt (Tables)
Convertible Debt (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Debt Disclosure [Abstract] | |
Outstanding Convertible Debt and Related Deferred Financing Costs | The Company had outstanding convertible debt and related deferred financing costs on its consolidated balance sheet as follows: As of (in thousands) March 31, 2017 December 31, 2016 Principal amount of the 2% Convertible Senior Notes $ 67,084 $ 67,084 Principal amount of the 1.25% Convertible Senior Notes 345,000 345,000 Unamortized debt discount (66,180 ) (69,684 ) Deferred financing costs (9,142 ) (9,632 ) Long-term debt, net of discount $ 336,762 $ 332,768 |
Interest and Other Expense | Interest expense related to the convertible notes was as follows: Three Months Ended March 31, (in thousands) 2017 2016 Contractual coupon interest $ 1,413 $ 1,006 Accretion of debt discount 3,504 1,702 Amortization of debt issuance costs 490 282 Total interest and other expense $ 5,407 $ 2,990 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Disclosure Potential Common Shares Excluded From Computation Of Diluted Net Loss Per Share [Abstract] | |
Potential Common Shares Excluded from Computation of Diluted Net Loss per Share | Potential dilutive common share equivalents consist of the following: Three Months Ended March 31, 2017 2016 2.00% Convertible Senior Notes 1,442,433 4,327,257 1.25% Convertible Senior Notes 5,910,954 — Unvested restricted stock units 1,023,386 1,150,720 Outstanding options 3,571,559 3,594,297 Total dilutive common share equivalents 11,948,332 9,072,274 |
Accounts Receivable, Net (Table
Accounts Receivable, Net (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Receivables [Abstract] | |
Schedule of accounts receivable from major customers | Revenue for customers comprising more than 10% of total revenue were as follows: Three Months Ended March 31, 2017 2016 Amgen, Inc. 15% 17% Ypsomed Distribution AG 21% 15% RGH Enterprises, Inc. 10% 10% Customers that represented greater than 10% of gross accounts receivable as of March 31, 2017 and December 31, 2016 were as follows: As of March 31, 2017 December 31, 2016 Amgen, Inc. 10 % 16 % Ypsomed Distribution AG 28 % 19 % |
Components of Accounts Receivable | The components of accounts receivable are as follows: (in thousands) March 31, 2017 December 31, 2016 Trade receivables $ 43,348 $ 31,714 Allowance for doubtful accounts (2,700 ) (2,911 ) Total accounts receivable, net $ 40,648 $ 28,803 |
Inventories, Net (Tables)
Inventories, Net (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Disclosure Components Of Inventories [Abstract] | |
Components of Inventories | The components of inventories are as follows: As of (in thousands) March 31, 2017 December 31, 2016 Raw materials $ 2,284 $ 1,911 Work-in-process 12,925 15,681 Finished goods, net 19,124 17,922 Total inventories $ 34,333 $ 35,514 |
Other Intangible Assets (Tables
Other Intangible Assets (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Components of Other Intangible Assets | The components of other intangible assets are as follows: As of March 31, 2017 December 31, 2016 (in thousands) Gross Carrying Amount Accumulated Amortization Net Book Value Gross Carrying Amount Accumulated Amortization Net Book Value Customer and contractual relationships, net (1) $ 2,011 $ (1,524 ) $ 487 $ 1,994 $ (1,466 ) $ 528 Internal-use software 4,471 (2,750 ) 1,721 4,064 (2,551 ) 1,513 Total intangible assets $ 6,482 $ (4,274 ) $ 2,208 $ 6,058 $ (4,017 ) $ 2,041 ____________________________________ (1) Includes foreign currency translation loss of approximately $0.1 million . |
Amortization Expense Expected for Next Five Years | Amortization expense expected for the next five years and thereafter is as follows: (in thousands) Years Ending December 31, Customer and Contractual Relationships Internal-Use Software (1) Total 2017 (remaining) $ 138 $ 506 $ 644 2018 157 466 623 2019 131 178 309 2020 61 7 68 Total $ 487 $ 1,157 $ 1,644 ____________________________________ (1) Excludes software in-process of development that is not currently being amortized. |
Accrued Expenses and Other Cu33
Accrued Expenses and Other Current Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Payables and Accruals [Abstract] | |
Components of accrued expenses and other current liabilities | The components of accrued expenses and other current liabilities are as follows: (in thousands) March 31, 2017 December 31, 2016 Employee compensation and related costs $ 15,051 $ 21,999 Professional and consulting services 7,300 6,753 Supplier charges 1,893 2,886 Warranty 1,705 1,642 Other 5,890 7,948 Total accrued expenses and other current liabilities $ 31,839 $ 41,228 |
Reconciliation of Changes in Product Warranty Liability | A reconciliation of the changes in the Company’s product warranty liability is as follows: Three Months Ended March 31, (in thousands) 2017 2016 Balance at the beginning of the period $ 4,388 $ 4,152 Warranty expense 1,463 1,028 Warranty claims settled (1,289 ) (1,020 ) Balance at the end of the period $ 4,562 $ 4,160 (in thousands) March 31, 2017 December 31, 2016 Composition of balance: Short-term $ 1,705 $ 1,642 Long-term 2,857 2,746 $ 4,562 $ 4,388 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Commitments and Contingencies Disclosure [Abstract] | |
Aggregate future minimum lease payments | The aggregate future minimum lease payments related to these leases as of March 31, 2017 are as follows: (in thousands) Years Ending December 31, Minimum Lease Payments 2017 (remaining) $ 2,065 2018 2,684 2019 2,681 2020 2,402 2021 2,383 Thereafter 2,131 Total $ 14,346 |
Equity (Tables)
Equity (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Disclosure of compensation related costs, share-based payments | The following table reflects the Company's stock-based compensation expense related to share-based awards recognized in the three months ended March 31, 2017 and 2016 : Three Months Ended March 31, Unamortized Expense Weighted Average Remaining Contractual Life (Years) ($ in thousands) 2017 2016 At March 31, 2017 Stock options $ 2,779 $ 2,321 $ 23,067 2.7 Restricted stock units 4,237 2,950 33,359 2.3 Employee stock purchase plan 108 — 72 0.2 Total $ 7,124 $ 5,271 $ 56,498 |
Stock option activity | The following summarizes the activity under the Company’s stock option plans during the three months ended March 31, 2017 : Number of Options (#) Weighted Average Exercise Price ($) Aggregate Intrinsic Value ($ in 000s) Weighted Average Remaining Contractual Life (Years) Balance, December 31, 2016 3,441,303 $ 32.27 Granted 416,244 45.19 Exercised (1) (260,290 ) 24.34 $ 4,882 Canceled (25,698 ) 33.85 Balance, March 31, 2017 3,571,559 $ 34.35 $ 32,610 8.2 Vested, March 31, 2017 (2) 1,540,298 $ 33.17 $ 15,447 7.5 Vested and expected to vest, March 31, 2017 (2)(3) 3,275,247 $ 30,325 (1) The aggregate intrinsic value was calculated based on the positive difference between the estimated fair value of the Company’s common stock as of the date of exercise and the exercise price of the underlying options. The aggregate intrinsic value of options exercised in the three months ended March 31, 2017 and 2016 was $4.9 million and $0.8 million , respectively. (2) The aggregate intrinsic value was calculated based on the positive difference between the estimated fair value of the Company’s common stock as of March 31, 2017 , and the exercise price of the underlying options. (3) Represents the number of vested options as of March 31, 2017 , plus the number of unvested options expected to vest as of March 31, 2017 , based on the unvested options outstanding at March 31, 2017 adjusted for the estimated forfeiture. |
Summary of restricted stock units | The following table summarizes the status of the Company’s restricted stock units during the three months ended March 31, 2017 : Number of Shares (#) Weighted Average Fair Value ($) Balance, December 31, 2016 962,219 $ 31.14 Granted 330,619 46.22 Vested (266,495 ) 32.03 Forfeited (2,957 ) 33.17 Balance, March 31, 2017 1,023,386 $ 35.77 |
Segment Reporting (Tables)
Segment Reporting (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Segment Reporting [Abstract] | |
Worldwide revenue by products | Worldwide revenue for the Company's products is categorized as follows: Three Months Ended March 31, (in thousands) 2017 2016 U.S. Omnipod $ 59,655 $ 50,712 International Omnipod 25,144 15,380 Drug Delivery 16,914 15,121 Total $ 101,713 $ 81,213 |
Geographic information about revenue | Geographic information about revenue, based on the region of the customer's shipping location, is as follows: Three Months Ended March 31, (in thousands) 2017 2016 United States $ 76,569 $ 65,833 All other 25,144 15,380 Total $ 101,713 $ 81,213 |
Geographic information about long-lived assets | Geographic information about long-lived assets, net, excluding goodwill and other intangible assets is as follows: (in thousands) March 31, 2017 December 31, 2016 United States $ 43,238 $ 19,341 China 22,203 25,431 Other 71 197 Total $ 65,512 $ 44,969 |
Nature of Business (Details)
Nature of Business (Details) | Mar. 31, 2017in |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Number of inches of tubing in conventional insulin pump (in inches) | 42 |
Summary of Significant Accoun38
Summary of Significant Accounting Policies (Details) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2017USD ($)segmentlocation | Mar. 31, 2016USD ($) | Dec. 31, 2016USD ($) | |
Significant Accounting Policies [Line Items] | |||
Foreign currency transaction gain (loss), before tax | $ 0 | $ 0 | |
Restricted cash | 1,200,000 | $ 1,200,000 | |
Property and equipment, accumulated depreciation | $ 42,000,000 | 39,000,000 | |
Number of operating segments (in segments) | segment | 1 | ||
Goodwill impairment loss | $ 0 | 0 | |
Return period | 45 days | ||
Return period Canada | 90 days | ||
Deferred revenue | $ 1,800,000 | $ 1,900,000 | |
Shipping and handling costs | $ 1,300,000 | $ 1,000,000 | |
Number of accredited financial institutions which the Company maintains the majority of its cash | location | 1 | ||
Percentage of accounts payable, accrued expenses, and other current liabilities | 9.00% | 16.00% | |
Reclassification of internal use software | $ (65,279,000) | $ (44,753,000) | |
Increase in finite-lived intangible assets | 2,208,000 | 2,041,000 | |
Increase to accumulated amortization | $ 4,274,000 | 4,017,000 | |
Total revenue | Customer concentration risk | Amgen, Inc. | |||
Significant Accounting Policies [Line Items] | |||
Concentration risk, percentage | 15.00% | 17.00% | |
Total revenue | Customer concentration risk | Ypsomed Distribution AG | |||
Significant Accounting Policies [Line Items] | |||
Concentration risk, percentage | 21.00% | 15.00% | |
Total revenue | Customer concentration risk | RGH Enterprises, Inc. | |||
Significant Accounting Policies [Line Items] | |||
Concentration risk, percentage | 10.00% | 10.00% | |
Other long-term liabilities | |||
Significant Accounting Policies [Line Items] | |||
Deferred revenue | $ 700,000 | 600,000 | |
Accounting Standards Update 2016-09 | Pro Forma | |||
Significant Accounting Policies [Line Items] | |||
Deferred tax assets, net | 23,800,000 | ||
Internal-use software | Accounting Standards Update 2016-19 | |||
Significant Accounting Policies [Line Items] | |||
Property and equipment, accumulated depreciation | (2,600,000) | ||
Reclassification of internal use software | 1,513,000 | ||
Internal-use software | |||
Significant Accounting Policies [Line Items] | |||
Increase in finite-lived intangible assets | 1,721,000 | 1,513,000 | |
Increase to accumulated amortization | $ 2,750,000 | 2,551,000 | |
Internal-use software | Accounting Standards Update 2016-19 | |||
Significant Accounting Policies [Line Items] | |||
Increase in finite-lived intangible assets | 1,500,000 | ||
Increase to accumulated amortization | $ 2,600,000 |
Discontinued Operations - Narra
Discontinued Operations - Narrative (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | ||
Jun. 30, 2016 | Feb. 28, 2016 | Mar. 31, 2017 | Mar. 31, 2016 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Discontinued operation, period of continuing involvement after disposal | 6 months | |||
Discontinued operation, intra-entity amounts, discontinued operation after disposal, expense | $ 0 | $ 300 | ||
Revenue | 101,713 | 81,213 | ||
Depreciation and amortization, discontinued operations | 0 | 100 | ||
Cash provided by (used in) operating activities, discontinued operations | 0 | 2,000 | ||
Neighborhood Diabetes | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Revenue | 300 | |||
Neighborhood Diabetes | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Proceeds from divestiture of interest in subsidiaries and affiliates | $ 1,200 | $ 6,200 | ||
Neighborhood Diabetes | Neighborhood Diabetes | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Discontinued operation, intra-entity amounts, discontinued operation after disposal, revenue | $ 0 | $ 400 |
Discontinued Operations - Incom
Discontinued Operations - Income Statement Disclosures (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2017 | Mar. 31, 2016 | ||
Operating expenses: | |||
Income tax expense | $ 0 | $ 408 | |
Net loss from discontinued operations | $ 0 | (1,792) | |
Neighborhood Diabetes | |||
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract] | |||
Revenue | [1] | 7,730 | |
Cost of revenue | 5,369 | ||
Gross profit | 2,361 | ||
Operating expenses: | |||
Sales and marketing | 1,536 | ||
General and administrative | [2] | 2,081 | |
Total operating expenses | 3,617 | ||
Operating loss | (1,256) | ||
Interest and other income (expense), net | (128) | ||
Loss from discontinued operations before taxes | (1,384) | ||
Income tax expense | 408 | ||
Net loss from discontinued operations | (1,792) | ||
Loss on sale of discontinued operations | $ 1,264 | ||
[1] | (1) Revenue includes revenue from the operations of Neighborhood Diabetes through date of sale in February 2016. | ||
[2] | (2) Includes $1.3 million loss on sale of Neighborhood Diabetes. |
Fair Value Measurements - Sched
Fair Value Measurements - Schedule of Assets Measured on a Recurring and Nonrecurring Basis (Details) - Recurring fair value measurements: - USD ($) | Mar. 31, 2017 | Dec. 31, 2016 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | $ 67,278,000 | $ 98,405,000 |
Short-term investments: | 177,990,000 | 161,396,000 |
Money market mutual funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 63,445,000 | 93,467,000 |
Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 3,833,000 | 4,203,000 |
Short-term investments: | 53,884,000 | 56,653,000 |
Certificates of deposit | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 0 | 735,000 |
Short-term investments: | 24,354,000 | 25,650,000 |
U.S. government and agency bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Short-term investments: | 99,752,000 | 79,093,000 |
Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 63,445,000 | 93,467,000 |
Short-term investments: | 67,414,000 | 49,963,000 |
Level 1 | Money market mutual funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 63,445,000 | 93,467,000 |
Level 1 | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 0 | 0 |
Short-term investments: | 0 | 0 |
Level 1 | Certificates of deposit | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 0 | 0 |
Short-term investments: | 67,414,000 | 0 |
Level 1 | U.S. government and agency bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Short-term investments: | 0 | 49,963,000 |
Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 3,833,000 | 4,938,000 |
Short-term investments: | 110,576,000 | 111,433,000 |
Level 2 | Money market mutual funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 0 | 0 |
Level 2 | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 3,833,000 | 4,203,000 |
Short-term investments: | 24,354,000 | 56,653,000 |
Level 2 | Certificates of deposit | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 0 | 735,000 |
Short-term investments: | 32,338,000 | 25,650,000 |
Level 2 | U.S. government and agency bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Short-term investments: | 53,884,000 | 29,130,000 |
Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 0 | 0 |
Short-term investments: | 0 | 0 |
Level 3 | Money market mutual funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 0 | 0 |
Level 3 | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 0 | 0 |
Short-term investments: | 0 | 0 |
Level 3 | Certificates of deposit | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents: | 0 | 0 |
Short-term investments: | 0 | 0 |
Level 3 | U.S. government and agency bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Short-term investments: | $ 0 | $ 0 |
Fair Value Measurements - Sch42
Fair Value Measurements - Schedule of Liabilities Measure on Recurring and Nonrecurring Basis (Details) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2014 |
2% Convertible Senior Notes | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Debt, interest rate | 2.00% | 2.00% | ||
1.25% Convertible Senior Notes | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Debt, interest rate | 1.25% | 1.25% | ||
Carrying Value | 2% Convertible Senior Notes | Level 2 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Financial instrument value | $ 60,429 | $ 59,737 | ||
Carrying Value | 1.25% Convertible Senior Notes | Level 2 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Financial instrument value | 276,333 | 273,031 | ||
Estimated Fair Value | 2% Convertible Senior Notes | Level 2 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Financial instrument value | 75,865 | 71,909 | ||
Estimated Fair Value | 1.25% Convertible Senior Notes | Level 2 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Financial instrument value | $ 347,556 | $ 320,969 |
Short-term Investments (Details
Short-term Investments (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Dec. 31, 2016 | |
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized cost | $ 178,207 | $ 161,603 |
Gross Unrealized Gains | 3 | 0 |
Gross Unrealized Losses | (220) | (207) |
Fair Value | 177,990 | 161,396 |
U.S. government and agency bonds | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized cost | 99,922 | 79,211 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (170) | (118) |
Fair Value | 99,752 | 79,093 |
Corporate bonds | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized cost | 53,931 | 56,742 |
Gross Unrealized Gains | 3 | 0 |
Gross Unrealized Losses | (50) | (89) |
Fair Value | 53,884 | 56,653 |
Certificates of deposit | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized cost | 24,354 | 25,650 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | $ 24,354 | $ 25,650 |
Minimum | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Available for sale securities, length of time until maturity date | 0 months | |
Maximum | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Available for sale securities, length of time until maturity date | 18 months |
Convertible Debt - Outstanding
Convertible Debt - Outstanding Convertible Debt and Related Deferred Financing Costs (Details) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2014 |
Debt Instrument [Line Items] | ||||
Unamortized debt discount | $ (66,180) | $ (69,684) | ||
Deferred financing costs | (9,142) | (9,632) | ||
Long-term debt, net of discount | 336,762 | 332,768 | ||
2% Convertible Senior Notes | ||||
Debt Instrument [Line Items] | ||||
Principal amount of Senior Notes | $ 67,084 | 67,084 | ||
Debt, interest rate | 2.00% | 2.00% | ||
1.25% Convertible Senior Notes | ||||
Debt Instrument [Line Items] | ||||
Principal amount of Senior Notes | $ 345,000 | $ 345,000 | ||
Debt, interest rate | 1.25% | 1.25% |
Convertible Debt - Interest Exp
Convertible Debt - Interest Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Debt Disclosure [Abstract] | ||
Contractual coupon interest | $ 1,413 | $ 1,006 |
Accretion of debt discount | 3,504 | 1,702 |
Amortization of debt issuance costs | 490 | 282 |
Total interest and other expense | $ 5,407 | $ 2,990 |
Convertible Debt - Narrative (D
Convertible Debt - Narrative (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||
Sep. 30, 2016 | Jun. 30, 2014 | Mar. 31, 2017 | Mar. 31, 2016 | Dec. 31, 2016 | |
Debt Instrument [Line Items] | |||||
Unamortized discount | $ 66,180,000 | $ 69,684,000 | |||
Amortization of debt discount and debt issuance costs | $ 3,994,000 | $ 1,984,000 | |||
1.25% Convertible Senior Notes | |||||
Debt Instrument [Line Items] | |||||
Principal amount of senior notes | $ 345,000,000 | ||||
Debt, interest rate | 1.25% | 1.25% | |||
Debt conversion rate | 17.1332 | ||||
Principal amount per note used in conversion rate | $ 1,000 | ||||
Conversion price, per share (USD per share) | $ 58.37 | ||||
Nonconvertible debt borrowing rate | 5.80% | ||||
Debt discount amortization period | 5 years | ||||
Deferred financing costs, gross | $ 11,300,000 | ||||
Finance costs reclassified against equity | $ 2,200,000 | ||||
Deferred financing costs, amortization period | 5 years | ||||
Debt instrument, additional interest in event of reporting violation | 0.50% | ||||
Interest expense related to Notes | $ 1,100,000 | ||||
Amortization of debt discount and debt issuance costs | 3,300,000 | ||||
Long-term debt | $ 276,300,000 | ||||
Debt instrument, redemption period | 360 days | ||||
1.25% Convertible Senior Notes | Investor | |||||
Debt Instrument [Line Items] | |||||
Unamortized discount | $ 66,700,000 | ||||
2% Convertible Senior Notes | |||||
Debt Instrument [Line Items] | |||||
Principal amount of senior notes | $ 201,300,000 | ||||
Debt, interest rate | 2.00% | 2.00% | |||
Debt conversion rate | 21.5019 | ||||
Principal amount per note used in conversion rate | $ 1,000 | ||||
Conversion price, per share (USD per share) | $ 46.51 | ||||
Nonconvertible debt borrowing rate | 6.20% | ||||
Debt discount amortization period | 5 years | ||||
Deferred financing costs, gross | $ 6,700,000 | ||||
Finance costs reclassified against equity | $ 1,200,000 | ||||
Deferred financing costs, amortization period | 5 years | ||||
Interest expense related to Notes | $ 300,000 | 1,000,000 | |||
Amortization of debt discount and debt issuance costs | 700,000 | $ 2,000,000 | |||
Long-term debt | $ 60,400,000 | ||||
Amount allocated to debt | 121,400,000 | 121,400,000 | |||
Amount allocated to equity | 32,900,000 | ||||
Loss on extinguishment of long-term debt | $ (2,600,000) | ||||
2% Convertible Senior Notes | Up to 360 days | |||||
Debt Instrument [Line Items] | |||||
Debt instrument, additional interest in event of reporting violation | 0.25% | ||||
Debt instrument, redemption period | 180 days | ||||
2% Convertible Senior Notes | First 180 days | |||||
Debt Instrument [Line Items] | |||||
Debt instrument, additional interest in event of reporting violation | 0.50% | ||||
Debt instrument, redemption period | 360 days | ||||
2% Convertible Senior Notes | Investor | |||||
Debt Instrument [Line Items] | |||||
Unamortized discount | $ 35,600,000 | ||||
2% Convertible Senior Notes | Investor | |||||
Debt Instrument [Line Items] | |||||
Principal amount of senior notes | 134,200,000 | ||||
Payments of long-term debt | $ 153,600,000 |
Net Loss Per Share - Potential
Net Loss Per Share - Potential Common Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total dilutive common shares (in shares) | 11,948,332 | 9,072,274 |
2% Convertible Senior Notes | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total dilutive common shares (in shares) | 1,442,433 | 4,327,257 |
Debt, interest rate | 2.00% | |
1.25% Convertible Senior Notes | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total dilutive common shares (in shares) | 5,910,954 | 0 |
Debt, interest rate | 1.25% | |
Unvested restricted stock units | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total dilutive common shares (in shares) | 1,023,386 | 1,150,720 |
Outstanding options | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total dilutive common shares (in shares) | 3,571,559 | 3,594,297 |
Accounts Receivable, Net (Detai
Accounts Receivable, Net (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2017 | Dec. 31, 2016 | |
Concentration Risk [Line Items] | ||
Trade receivables | $ 43,348 | $ 31,714 |
Allowance for doubtful accounts | (2,700) | (2,911) |
Total accounts receivable, net | $ 40,648 | $ 28,803 |
Amgen, Inc. | Customer concentration risk | Accounts receivable | ||
Concentration Risk [Line Items] | ||
Concentration risk, percentage | 10.00% | 16.00% |
Ypsomed Distribution AG | Customer concentration risk | Accounts receivable | ||
Concentration Risk [Line Items] | ||
Concentration risk, percentage | 28.00% | 19.00% |
Inventories, Net - Components o
Inventories, Net - Components of Inventories (Detail) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 |
Disclosure Components Of Inventories [Abstract] | ||
Raw materials | $ 2,284 | $ 1,911 |
Work-in-process | 12,925 | 15,681 |
Finished goods, net | 19,124 | 17,922 |
Total inventories | $ 34,333 | $ 35,514 |
Other Intangible Assets - Narra
Other Intangible Assets - Narrative (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | ||
Jul. 31, 2015 | Mar. 31, 2017 | Mar. 31, 2016 | Dec. 31, 2016 | |
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Property and equipment, net | $ (65,279) | $ (44,753) | ||
Increase in finite-lived intangible assets | 2,208 | 2,041 | ||
Amortization of other intangible assets | $ 300 | $ 100 | ||
Intangible asset, weighted average amortization period | 2 years 6 months | |||
Customer and Contractual Relationships | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Increase in finite-lived intangible assets | $ 487 | 528 | ||
Internal-use software | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Increase in finite-lived intangible assets | $ 1,721 | 1,513 | ||
GSK Asset Acquisition | Customer and Contractual Relationships | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Other intangible assets cost | $ 2,100 | |||
GSK Asset Acquisition | Customer and Contractual Relationships | Maximum | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Estimated useful life | 5 years | |||
Accounting Standards Update 2016-19 | Internal-use software | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Increase in finite-lived intangible assets | 1,500 | |||
Internal-use software | Accounting Standards Update 2016-19 | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Property and equipment, net | $ 1,513 |
Other Intangible Assets - Compo
Other Intangible Assets - Components of Other Intangible Assets (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Dec. 31, 2016 | |
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | $ 6,482 | $ 6,058 |
Accumulated Amortization | (4,274) | (4,017) |
Net Book Value | 2,208 | 2,041 |
Customer and Contractual Relationships | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 2,011 | 1,994 |
Accumulated Amortization | (1,524) | (1,466) |
Net Book Value | 487 | 528 |
Finite lived intangible assets, foreign currency translation gain (loss) | (100) | |
Internal-use software | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 4,471 | 4,064 |
Accumulated Amortization | (2,750) | (2,551) |
Net Book Value | $ 1,721 | $ 1,513 |
Other Intangible Assets - Amort
Other Intangible Assets - Amortization Expense Expected for Next Five Years (Details) $ in Thousands | Mar. 31, 2017USD ($) |
Expected Amortization Expense [Line Items] | |
2017 (remaining) | $ 644 |
2,018 | 623 |
2,019 | 309 |
2,020 | 68 |
Net Book Value | 1,644 |
Customer and Contractual Relationships | |
Expected Amortization Expense [Line Items] | |
2017 (remaining) | 138 |
2,018 | 157 |
2,019 | 131 |
2,020 | 61 |
Net Book Value | 487 |
Internal-use software | |
Expected Amortization Expense [Line Items] | |
2017 (remaining) | 506 |
2,018 | 466 |
2,019 | 178 |
2,020 | 7 |
Net Book Value | $ 1,157 |
Accrued Expenses and Other Cu53
Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 |
Payables and Accruals [Abstract] | ||
Employee compensation and related costs | $ 15,051 | $ 21,999 |
Professional and consulting services | 7,300 | 6,753 |
Supplier charges | 1,893 | 2,886 |
Warranty | 1,705 | 1,642 |
Other | 5,890 | 7,948 |
Total accrued expenses and other current liabilities | $ 31,839 | $ 41,228 |
Accrued Expenses and Other Cu54
Accrued Expenses and Other Current Liabilities - Narrative (Details) | 3 Months Ended |
Mar. 31, 2017 | |
United States | |
Product Warranty Liability [Line Items] | |
Product warranty term for PDMs | 4 years |
CANADA | |
Product Warranty Liability [Line Items] | |
Product warranty term for PDMs | 5 years |
Accrued Expenses and Other Cu55
Accrued Expenses and Other Current Liabilities - Product Warranty Liability (Details) - USD ($) $ in Thousands | 3 Months Ended | |||
Mar. 31, 2017 | Mar. 31, 2016 | Mar. 31, 2017 | Dec. 31, 2016 | |
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward] | ||||
Balance at the beginning of the period | $ 4,388 | $ 4,152 | ||
Warranty expense | 1,463 | 1,028 | ||
Warranty claims settled | (1,289) | (1,020) | ||
Balance at the end of the period | 4,562 | 4,160 | ||
Composition of balance: | ||||
Short-term | $ 1,705 | $ 1,642 | ||
Long-term | 2,857 | 2,746 | ||
Total warranty balance | $ 4,388 | $ 4,152 | $ 4,562 | $ 4,388 |
Commitments and Contingencies -
Commitments and Contingencies - Legal Proceedings (Details) ft² in Thousands, $ in Millions | 1 Months Ended | 3 Months Ended | 15 Months Ended | |||||
May 31, 2016USD ($) | Apr. 30, 2016USD ($) | Jun. 16, 2015LegalMatter | Mar. 31, 2017USD ($)ft² | Mar. 31, 2016USD ($) | Sep. 30, 2016LegalMatter | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | |
Loss Contingencies [Line Items] | ||||||||
Operating leases, rent expense | $ 0.6 | $ 0.6 | ||||||
Loss accrual | $ 0.3 | $ 0.4 | ||||||
Number of class actions filed (in legal matters) | LegalMatter | 3 | |||||||
Number of class actions dismissed (in legal matters) | LegalMatter | 2 | |||||||
Massachusetts Department of Revenue | ||||||||
Loss Contingencies [Line Items] | ||||||||
Litigation settlement, expense | $ 0.5 | |||||||
Reduction to accrual | $ 0.2 | |||||||
Connecticut Department of Social Services Office of Quality Assurance Audit | ||||||||
Loss Contingencies [Line Items] | ||||||||
Litigation settlement | $ 0.5 | |||||||
Laboratory And Office Space | Billerica Massachusetts | ||||||||
Loss Contingencies [Line Items] | ||||||||
Area of real estate property | ft² | 100 | |||||||
Warehouse | Billerica Massachusetts | ||||||||
Loss Contingencies [Line Items] | ||||||||
Area of real estate property | ft² | 29 | |||||||
Property, Plant and Equipment, Other Types | ||||||||
Loss Contingencies [Line Items] | ||||||||
Area of real estate property | ft² | 11 |
Commitments and Contingencies57
Commitments and Contingencies - Aggregate Future Minimum Lease Payments (Details) $ in Thousands | Mar. 31, 2017USD ($) |
Minimum Lease Payments | |
2017 (remaining) | $ 2,065 |
2,018 | 2,684 |
2,019 | 2,681 |
2,020 | 2,402 |
2,021 | 2,383 |
Thereafter | 2,131 |
Total | $ 14,346 |
Equity Schedule of Stock-Based
Equity Schedule of Stock-Based Compensation Expense Related to Share-Based Awards (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Stock-based compensation expense | $ 7,124 | $ 5,271 |
Total unrecognized compensation expense | 56,498 | |
Stock options | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Stock-based compensation expense | 2,779 | 2,321 |
Total unrecognized compensation expense | $ 23,067 | |
Share-based compensation arrangement by share-based payment award, options, vested and expected to vest, exercisable, weighted average remaining contractual term | 2 years 8 months 12 days | |
Unvested restricted stock units | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Stock-based compensation expense | $ 4,237 | 2,950 |
Total unrecognized compensation expense | $ 33,359 | |
Share-based compensation arrangement by share-based payment award, equity instruments other than options, outstanding, weighted average remaining contractual terms | 2 years 3 months 18 days | |
Employee Stock Purchase Plans | ||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||
Stock-based compensation expense | $ 108 | $ 0 |
Total unrecognized compensation expense | $ 72 | |
Share-based compensation arrangement by share-based payment award, equity instruments other than options, outstanding, weighted average remaining contractual terms | 2 months 12 days |
Equity - Stock Options Narrativ
Equity - Stock Options Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | Dec. 31, 2015 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares available for future issuance (in shares) | 3,441,215 | ||
Shares granted during the period (in shares) | 416,244 | ||
Stock-based compensation expense | $ 7,124 | $ 5,271 | |
Total unrecognized compensation expense | $ 56,498 | ||
Stock options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting period | 4 years | ||
Expiration period | 10 years | ||
Stock-based compensation expense | $ 2,779 | $ 2,321 | |
Total unrecognized compensation expense | $ 23,067 | ||
Performance based stock options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares granted during the period (in shares) | 34,500 | 0 | |
Performance based stock options | Maximum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting period | 4 years |
Equity - Stock Option Activity
Equity - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Number of Options | ||
Beginning balance (in shares) | 3,441,303 | |
Granted (in shares) | 416,244 | |
Exercised (in shares) | (260,290) | |
Canceled (in shares) | (25,698) | |
Ending balance (in shares) | 3,571,559 | |
Vested, at end of period (in shares) | 1,540,298 | |
Vested and expected to vest, at end of period (in shares) | 3,275,247 | |
Weighted Average Exercise Price | ||
Beginning balance (in dollars per share) | $ 32.27 | |
Granted (in dollars per share) | 45.19 | |
Exercised (in dollars per share) | 24.34 | |
Canceled (in dollars per share) | 33.85 | |
Ending balance (in dollars per share) | 34.35 | |
Vested, at end of period (in dollars per share) | $ 33.17 | |
Aggregate Intrinsic Value | ||
Exercised | $ 4,882 | $ 800 |
Ending balance | 32,610 | |
Vested, at end of period | 15,447 | |
Vested and expected to vest, at end of period | $ 30,325 | |
Options outstanding, weighted average remaining contractual life | 8 years 2 months 12 days | |
Options exercisable, weighted average remaining contractual life | 7 years 6 months |
Equity - Restricted Stock Units
Equity - Restricted Stock Units Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | $ 7,124 | $ 5,271 |
Total unrecognized compensation expense | $ 56,498 | |
Unvested restricted stock units | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Shares granted during the period (in shares) | 330,619 | |
Stock-based compensation expense | $ 4,237 | 2,950 |
Other than options - granted in period, weighted average fair value (in dollars per share) | $ 46.22 | |
Other than options - grant date fair value (in dollars per share) | $ 15,300 | |
Total unrecognized compensation expense | $ 33,359 | |
Performance Shares | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Shares granted during the period (in shares) | 105,476 | |
Performance Shares | Maximum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Vesting period | 3 years | |
Performance Shares | Minimum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Vesting period | 1 year | |
Performance Based Restricted Stock Units - Performance Criteria Not Met | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | $ 1,000 | |
Performance Based Restricted Stock Units - Performance Criteria Met | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | 200 | |
Non-Performance Shares | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | $ 3,000 | $ 2,300 |
Equity - Summary of Restricted
Equity - Summary of Restricted Stock Units (Details) - Unvested restricted stock units | 3 Months Ended |
Mar. 31, 2017$ / sharesshares | |
Number of Shares | |
Beginning balance (in shares) | shares | 962,219 |
Granted (in shares) | shares | 330,619 |
Vested (in shares) | shares | (266,495) |
Forfeited (in shares) | shares | (2,957) |
Ending balance (in shares) | shares | 1,023,386 |
Weighted Average Grant Date Fair Value | |
Beginning balance (in dollars per share) | $ / shares | $ 31.14 |
Granted (in dollars per share) | $ / shares | 46.22 |
Vested (in dollars per share) | $ / shares | 32.03 |
Forfeited (in dollars per share) | $ / shares | 33.17 |
Ending balance (in dollars per share) | $ / shares | $ 35.77 |
Equity - Employee Stock Purchas
Equity - Employee Stock Purchase Plan Narrative (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | $ 7,124,000 | $ 5,271,000 |
Employee Stock Purchase Plans | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Number of shares authorized (in shares) | 380,000 | |
Annual maximum shares per employee (in shares) | 800 | |
Annual maximum value purchase per employee | $ 25,000 | |
Purchase price percentage of fair market value | 85.00% | |
Stock-based compensation expense | $ 108,000 | $ 0 |
Employee Stock Purchase Plans | Maximum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Percentage of employees' compensation deduction for share purchase | 10.00% |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Detail) - USD ($) | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Significant Accounting Policies [Line Items] | ||
Income tax expense | $ 96,000 | $ 64,000 |
Unrecognized tax benefits | $ 0 | |
Minimum | ||
Significant Accounting Policies [Line Items] | ||
Number of open tax years | 3 years | |
Maximum | ||
Significant Accounting Policies [Line Items] | ||
Number of open tax years | 4 years |
Segment Reporting (Details)
Segment Reporting (Details) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2017USD ($)segment | Mar. 31, 2016USD ($) | Dec. 31, 2016USD ($) | |
Segment Reporting Information [Line Items] | |||
Number of operating segments (in segments) | segment | 1 | ||
Revenues | $ 101,713 | $ 81,213 | |
Long-lived assets | 65,512 | $ 44,969 | |
United States | |||
Segment Reporting Information [Line Items] | |||
Revenues | 76,569 | 65,833 | |
Long-lived assets | 43,238 | 19,341 | |
All other | |||
Segment Reporting Information [Line Items] | |||
Revenues | 25,144 | 15,380 | |
China | |||
Segment Reporting Information [Line Items] | |||
Long-lived assets | 22,203 | 25,431 | |
Other | |||
Segment Reporting Information [Line Items] | |||
Long-lived assets | 71 | $ 197 | |
U.S. Omnipod | |||
Segment Reporting Information [Line Items] | |||
Revenues | 59,655 | 50,712 | |
International Omnipod | |||
Segment Reporting Information [Line Items] | |||
Revenues | 25,144 | 15,380 | |
Drug Delivery | |||
Segment Reporting Information [Line Items] | |||
Revenues | $ 16,914 | $ 15,121 |